1	Attention deficit hyperactivity disorder:
2	diagnosis and management
3	
4	NICE guideline: short version
5	Draft for consultation, September 2017
6	
	This guideline covers diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. This includes people with:
	a defined neurological disorder
	a mental health condition
	another neurodevelopmental disorder.
	Who is it for?

- people using services, their families and carers and the public
- primary, community and secondary health and social care professionals who care for children, young people and adults with ADHD

This guideline will update and replace NICE guideline CG72 (published September 2008).

We have updated or added new recommendations on recognition, information and support, managing ADHD (including non-pharmacological treatment), medication, follow-up and monitoring, adherence, and review of medication and discontinuation.

You are invited to comment on the new and updated recommendations in this guideline. These are marked as **[2018]**.

You are also invited to comment on recommendations that NICE proposes to delete from the 2008 guideline.

We have not updated recommendations shaded in grey, and cannot accept

comments on them. In some cases, we have made minor wording changes for clarification. These are indicated by yellow highlighting.

See <u>Update information</u> for a full explanation of what is being updated.

This version of the guideline contains:

- the draft recommendations
- rationale and impact sections that explain why the committee made the 2018 recommendations and how they might affect practice
- the guideline context
- recommendations for research.

Information about how the guideline was developed is on the <u>guideline's page</u> on the NICE website. This includes the evidence reviews, the scope, and details of the committee and any declarations of interest.

The supporting information and evidence for the 2018 recommendations is contained in the evidence reviews for the 2018 guideline. Evidence for the 2016 recommendations is in the <u>2016 addendum</u>. Evidence for the 2008 recommendations is in the <u>full version</u> of the 2008 guideline.

1

1 Contents

2	Conten	ts	3
3	Recom	mendations	4
4	1.1	Service organisation and training	4
5	1.2	Recognition, identification and referral	7
6	1.3	Diagnosis	9
7	1.4	Information and support	11
8	1.5	Managing ADHD	14
9	1.6	Dietary advice	
10	1.7	Medication	19
11	1.8	Follow-up and monitoring	26
12	1.9	Adherence to treatment	
13	1.10	Review of medication and discontinuation	31
14	Term	is used in this guideline	32
15	Recom	mendations for research	
16	Rationa	ale and impact	
17	Reco	gnition	
18	Infor	mation and support	
19	Mana	aging ADHD – planning treatment	
20	Mana	aging ADHD – children under 5 years	
21	Mana	aging ADHD – children and young people aged 5 years and over	
22	Mana	aging ADHD – adults	
23	Medi	cation – baseline assessment	
24	Medi	cation – choice	40
25	Medi	cation – initiation and titration	41
26	Medi	cation – monitoring side effects	
27	Adhe	erence to treatment	
28	Revie	ew of medication and discontinuation	43
29	Putting	this guideline into practice	44
30	Contex	t	45
31	Update	information	47
32			

1 **Recommendations**

People have the right to be involved in discussions and make informed decisions about their care, as described in <u>your care</u>.

Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

2 **1.1** Service organisation and training

3 Service organisation

- 4 1.1.1 People with attention deficit hyperactivity disorder (ADHD) would benefit
 5 from improved organisation of care and better integration of paediatric,
 6 child and adolescent mental health services (CAMHS) and adult mental
 7 health services. [2008]
- 8 1.1.2 Mental health services for children, young people and adults, and child
 9 health services, should form multidisciplinary specialist ADHD teams
 10 and/or clinics for children and young people and separate teams and/or
 11 clinics for adults. These teams and clinics should have expertise in the
 12 diagnosis and management of ADHD, and should:
- provide diagnostic, treatment and consultation services for people with
 ADHD who have complex needs, or where general psychiatric services
 are in doubt about the diagnosis and/or management of ADHD
- put in place systems of communication and protocols for information
 sharing among paediatric, child and adolescent, forensic, and adult
 mental health services for people with ADHD, including arrangements
 for transition between child and adult services
- produce local protocols for shared care arrangements with primary care
 providers, and ensure that clear lines of communication between
 primary and secondary care are maintained

1 2 3 4 5 6 7		 ensure age-appropriate psychological services are available for children, young people and adults with ADHD, and for parents or carers. The size and time commitment of these teams should depend on local circumstances (for example, the size of the trust, the population covered and the estimated referral rate for people with ADHD). [2008, amended 2018]
8 9 10 11 12 13 14	1.1.3	Every locality should develop a multi-agency group, with representatives from multidisciplinary specialist ADHD teams, paediatrics, mental health and learning disability trusts, forensic services, child and adolescent mental health services (CAMHS), the Directorate for Children and Young People (DCYP) (including services for education and social services), parent support groups and others with a significant local involvement in ADHD services. The group should:
 15 16 17 18 19 20 21 22 23 24 		 oversee the implementation of this guideline start and coordinate local training initiatives, including the provision of training and information for teachers about the characteristics of ADHD and its basic behavioural management oversee the development and coordination of parent-training/education programmes consider compiling a comprehensive directory of information and services for ADHD including advice on how to contact relevant services and assist in the development of specialist teams. [2008, amended 2018]
25 26 27 28 29 30 31	1.1.4	A young person with ADHD receiving treatment and care from CAMHS or paediatric services should be reassessed at school-leaving age to establish the need for continuing treatment into adulthood. If treatment is necessary, arrangements should be made for a smooth transition to adult services with details of the anticipated treatment and services that the young person will require. Precise timing of arrangements may vary locally but should usually be completed by the time the young person is

1		18 years. See NICE's guideline on transition from children's to adults'
2		services for young people using health or social care services. [2008,
3		amended 2018]
4	1.1.5	During the transition to adult services, a formal meeting involving CAMHS
5		and/or paediatrics and adult psychiatric services should be considered,
6		and full information provided to the young person about adult services.
7		For young people aged 16 years and older, the care programme approach
8		(CPA) should be used as an aid to transfer between services. The young
9		person, and when appropriate the parent or carer, should be involved in
10		the planning. [2008]
11	1.1.6	After transition to adult services, adult healthcare professionals should
12		carry out a comprehensive assessment of the person with ADHD that
13		includes personal, educational, occupational and social functioning, and
14		assessment of any coexisting conditions, especially drug misuse,
15		personality disorders, emotional problems and learning difficulties. [2008]
16	Training	
17	1.1.7	Trusts should ensure that specialist ADHD teams for children, young
18		people and adults jointly develop age-appropriate training programmes for
19		the diagnosis and management of ADHD for mental health, paediatric,
20		social care, education, forensic and primary care providers and other
21		professionals who have contact with people with ADHD. [2008]
22	1.1.8	Child and adult psychiatrists, paediatricians, and other child and adult
23		mental health professionals (including those working in forensic services)
24		should undertake training so that they are able to diagnose ADHD and
25		provide treatment and management in accordance with this guideline.
26		[2008]
27	1.1.9	The Department for Education should consider providing more education
28		to trainee teachers about ADHD by working with the Teaching Agency
29		and relevant health service organisations to produce training programmes
30		and guidance for supporting children with ADHD. [2008, amended 2018]

1

2 **1.2** *Recognition, identification and referral*

~	B	
3	Recognition	

4	1.2.1	Be aware that people in the following groups may have increased
5		prevalence of ADHD compared with the general population:
6		people born preterm (see NICE's guideline on <u>developmental follow-up</u>
7		of children and young people born preterm)
8		 looked-after children and young people
9		children and young people with oppositional defiant disorder or conduct
10		disorder
11		 children and young people with mood disorders (for example, anxiety
12		and depression)
13		 people with a close family member diagnosed with ADHD
14		 people with epilepsy
15		 people with neurodevelopmental disorders [for example, autism
16		spectrum disorder, tic disorders, learning disability (intellectual
17		disability) and specific learning difficulties]
18		 adults with a mental health condition (for example, psychosis)
19		 people with a history of substance misuse
20		 people within the secure estate
21		 people with acquired brain injury. [2018]
22	1.2.2	Be aware that ADHD is thought to be under-recognised in girls and
23		women and that they are:
24		 less likely to be referred for assessment for ADHD
25		 more likely to have undiagnosed ADHD
26		more likely to receive an incorrect diagnosis of another mental health or
27		neurodevelopmental condition. [2018]

To find out why the committee made the 2018 recommendations on recognition and how they might affect practice, see <u>rationale and impact</u>

1	Identifica	tion and referral
2	1.2.3	Universal screening for ADHD should not be undertaken in nursery,
3		primary and secondary schools. [2008]
4	1.2.4	When a child or young person with disordered conduct and suspected
5		ADHD is referred to a school's special educational needs coordinator
6		(SENCO), the SENCO, in addition to helping the child with their
7		behaviour, should inform the parents about local parent-training/education
8		programmes. See NICE's guideline on <u>antisocial behaviour and conduct</u>
9		disorders in children and young people. [2008, amended 2018]
10	1.2.5	Referral from the community to secondary care may involve health,
11		education and social care professionals (for example, GPs, paediatricians,
12		educational psychologists, SENCOs, social workers) and care pathways
13		can vary locally. The person making the referral to secondary care should
14		inform the child or young person's GP. [2008]
15	1.2.6	When a child or young person presents in primary care with behavioural
16		and/or attention problems suggestive of ADHD, primary care practitioners
17		should determine the severity of the problems, how these affect the child
18		or young person and the parents or carers and the extent to which they
19		pervade different domains and settings. [2008]
20	1.2.7	If the child or young person's behavioural and/or attention problems
21		suggestive of ADHD are having an adverse impact on their development
22		or family life, consider:
23		 a period of watchful waiting of up to 10 weeks
24		 offering parents or carers a referral to group-based ADHD-focused
25		support (this should not wait for a formal diagnosis of ADHD).
26		If the behavioural and/or attention problems persist with at least moderate
27		impairment, the child or young person should be referred to secondary
28		care (that is, a child psychiatrist, paediatrician, or specialist ADHD
29		CAMHS) for assessment. [2008, amended 2018]

1 2 3 4	1.2.8	If the child or young person's behavioural and/or attention problems are associated with severe impairment, referral should be made directly to secondary care (that is, a child psychiatrist, paediatrician, or specialist ADHD CAMHS) for assessment. [2008]
5 6	1.2.9	Primary care practitioners should not make the initial diagnosis or start medication in children or young people with suspected ADHD. [2008]
7 8 9 10 11 12	1.2.10	Adults presenting with symptoms of ADHD in primary care or general adult psychiatric services, who do not have a childhood diagnosis of ADHD, should be referred for assessment by a mental health specialist trained in the diagnosis and treatment of ADHD, where there is evidence of typical manifestations of ADHD (hyperactivity/impulsivity and/or inattention) that:
13 14 15 16 17 18		 began during childhood and have persisted throughout life are not explained by other psychiatric diagnoses (although there may be other coexisting psychiatric conditions) have resulted in or are associated with moderate or severe psychological, social and/or educational or occupational impairment. [2008]
 19 20 21 22 23 24 	1.2.11	Adults who have previously been treated for ADHD as children or young people and present with symptoms suggestive of continuing ADHD should be referred to general adult psychiatric services for assessment. The symptoms should be associated with at least moderate or severe psychological and/or social or educational or occupational impairment. [2008]
25	1.3	Diagnosis
26 27 28	1.3.1	A diagnosis of ADHD should only be made by a specialist psychiatrist, paediatrician or other appropriately qualified healthcare professional with training and expertise in the diagnosis of ADHD, on the basis of:

1 2 3 4 5		 a full clinical and psychosocial assessment of the person; this should include discussion about behaviour and symptoms in the different domains and settings of the person's everyday life, and a full developmental and psychiatric history, and observer reports and assessment of the person's mental state. [2008]
6 7 8 9 10	1.3.2	A diagnosis of ADHD should not be made solely on the basis of rating scale or observational data. However rating scales such as the Conners' rating scales and the Strengths and Difficulties questionnaire are valuable adjuncts, and observations (for example, at school) are useful when there is doubt about symptoms. [2008]
11 12	1.3.3	For a diagnosis of ADHD, symptoms of hyperactivity/impulsivity and/or inattention should:
 13 14 15 16 17 18 19 20 21 22 22 22 		 meet the diagnostic criteria in DSM-5 or ICD-10 (hyperkinetic disorder)¹, and cause at least moderate psychological, social and/or educational or occupational impairment based on interview and/or direct observation in multiple settings, and be pervasive, occurring in two or more important settings including social, familial, educational and/or occupational settings. As part of the diagnostic process, include an assessment of the person's needs, coexisting conditions, social, familial and educational or occupational circumstances and physical health. For children and young paperle, there about dates here accepted to the terms of the paperle.
23 24		people, there should also be an assessment of their parents' or carers' mental health. [2008, amended 2018]
25 26	1.3.4	ADHD should be considered in all age groups, with symptom criteria adjusted for age-appropriate changes in behaviour. [2008]

¹ The ICD-10 exclusion on the basis of a pervasive developmental disorder being present, or the time of onset being uncertain, is not recommended.

1.3.5 In determining the clinical significance of impairment resulting from the
 symptoms of ADHD in children and young people, their views should be
 taken into account wherever possible. [2008]

4 **1.4** Information and support

- 5 1.4.1 Use this guideline with the NICE guidelines on service user experience in adult mental health and patient experience in adult NHS services to
 7 improve the experience of care for adults with ADHD. The principles also
 8 apply to children and young people and their parents or carers. [2018]
- 9 1.4.2 Healthcare professionals working with children and young people with
- ADHD should follow the recommendations on general principles of care in NICE's guideline on <u>antisocial behaviour and conduct disorder in children</u> and young people. This does not mean that all children and young people with ADHD have coexisting antisocial behaviour and conduct disorder but that the same general principles of care apply when working with children and young people with ADHD. **[2018]**
- 161.4.3Provide information and support for people who have an assessment but17are not given a diagnosis of ADHD (for example, information about local18and national groups and voluntary organisations that offer support for their19situation). [2018]
- 20 Supporting people with ADHD
- 1.4.4 Following a diagnosis of ADHD, have a structured discussion with people
 (and their families or carers as appropriate) about how ADHD could affect
 their life. This could include:
- the positive impacts of receiving a diagnosis, such as:
- 25 improving their understanding of symptoms
- 26 identifying and building on individual strengths
- 27 improving access to services
- the negative impacts of receiving a diagnosis, such as stigma and
 labelling
- a greater tendency for impulsive behaviour

1		 the increased risk of substance misuse and self-medication
2		 the possible effect on driving (for example, some ADHD medication
3		may impact on a person's fitness to drive and people with ADHD must
4		declare their diagnosis to the DVLA if it affects their driving)
5		 the challenges of managing ADHD when a person has coexisting
6		neurodevelopmental or mental health conditions
7		 education and employment issues (for example, impact on career
8		choices and rights to reasonable adjustments at school and college,
9		and in the workplace)
10		 social relationship issues.
11		This should inform the shared treatment plan. [2018]
12	1.4.5	Tell people receiving a diagnosis of ADHD (and their families or carers as
13		appropriate) about:
14		 local and national support groups and voluntary organisations
15		 sources of more information, including websites
16		 support for education and employment. [2018]
17	1.4.6	Improve communication by providing information to people with ADHD
18		(and their families and carers as appropriate) that:
19		• takes into account their developmental level, cognitive style, emotional
20		maturity and cognitive capacity, including any learning disabilities, sight
21		or hearing problems, delays in language development or social
22		communication difficulties
23		 takes into account any coexisting neurodevelopmental and mental
24		health conditions
25		 is tailored to their individual needs and circumstances, including age,
26		gender, educational level and life stage. [2018]
27	Supporti	ing families and carers
28	1.4.7	Ask families or carers of people with ADHD how the ADHD affects
29		themselves and other family members, and discuss any concerns they
30		have. [2018]

1 2 3	1.4.8	Encourage family members or carers of people with ADHD to seek an assessment of their personal, social and mental health needs, and to join self-help and support groups if appropriate. [2018]
4 5	1.4.9	Offer advice to parents and carers of children and young people with ADHD about the importance of :
6		 positive parent – and carer –child contact
7		 clear and appropriate rules about behaviour
8		 structure in the child or young person's day. [2018]
9	1.4.10	Offer advice to families and carers of adults with ADHD about:
10		 how ADHD may affect relationships
11		 how ADHD may affect the person's functioning
12		• the importance of structure in daily activities. [2018]
13	1.4.11	Explain to parents and carers that any recommendation of parent-
14		training/education does not imply bad parenting, and that the aim is to
15		optimise parenting skills to meet the above-average parenting needs of
16		children and young people with ADHD. [2018]
17	Involving	g schools and colleges
18	1.4.12	When ADHD is diagnosed, when symptoms change, and when there is
19		transition between schools or from school to college, obtain consent and
20		then contact the school or college to explain:
21		 the validity of a diagnosis of ADHD and how symptoms are likely to
22		affect school or college life
23		 other coexisting conditions (for example, learning disabilities) are
24		distinct from ADHD and may need different adjustments
25		 the treatment plan and identified special educational needs, including
26		advice for environmental and learning modifications
27		 the value of feedback from schools and colleges to people with ADHD
28		and their healthcare professionals. [2018]

1 Involving other healthcare professionals

- 1.4.13 When a person with ADHD has a coexisting condition, contact the
 relevant healthcare professional, with consent, to explain:
- the validity, scope and implications of a diagnosis of ADHD
- how ADHD symptoms are likely to affect the person's behaviour (for
 example, organisation, time management) and adherence to specific
 treatments
 - the treatment plan and the value of feedback from healthcare professionals. [2018]

To find out why the committee made the 2018 recommendations on information and support and how they might affect practice, see <u>rationale and impact</u>

10

8 9

11 1.5 Managing ADHD

12 **Planning treatment**

- 13 1.5.1 Healthcare providers should ensure continuity of care for people with
 ADHD. [2018]
- 15 1.5.2 Ensure that people with ADHD have a comprehensive, holistic shared
 16 treatment plan that addresses psychological, behavioural and
 17 occupational or educational needs. Take into account:
- the severity of ADHD symptoms and how these affect or may affect a
 person's life
- their goals
- the level of impairment and impact on their everyday life
- their resilience and protective factors
- the relative impact of other neurodevelopmental or mental health
 conditions. [2018]
- 1.5.3 Regularly discuss with people with ADHD, and their family members or
 carers, how they want to be involved in treatment planning and decisions;

1 such discussions should take place at intervals to take account of any 2 changes in circumstances, including developmental level, and should not 3 happen only once. [2018] 1.5.4 4 Before starting any treatment for ADHD, discuss the following with the person, and their family or carers as appropriate, encouraging children 5 and young people to give their own account of how they feel: 6 7 the benefits and harms of non-pharmacological and pharmacological 8 treatments (for example, the efficacy of medications compared with no 9 treatment or non-pharmacological treatments, potential side effects and 10 non-response rates) 11 the benefits of a healthy lifestyle, including exercise 12 their preferences and concerns (for example, a person's decision to 13 start, change or stop treatment may be influenced by media coverage, 14 teachers, family members, friends and differing opinion on the validity 15 of ADHD and specific treatments) how other mental health or neurodevelopmental conditions might affect 16 17 treatment choices 18 the importance of adherence to treatment and any factors that may 19 affect this (for example, it may be difficult to take medication at school 20 or work). 21 Record the person's preferences and concerns in their treatment plan. 22 [2018] 1.5.5 23 Ask young people and adults with ADHD if a parent, partner, close friend 24 or carer could join discussions on treatment and adherence. [2018] 1.5.6 Reassure people with ADHD, and their families or carers as appropriate, 25 26 that they can revisit decisions about treatments. [2018]

To find out why the committee made the 2018 recommendations on managing ADHD – planning treatment and how they might affect practice, see <u>rationale and</u> <u>impact</u>.

1

2 Children under 5 years

- 1.5.7 Offer an ADHD-focused group parent-training programme to parents or
 carers of children under 5 years with ADHD as first-line treatment. See
 recommendations 1.5.1 to 1.5.10 in NICE's guideline on <u>antisocial</u>
 <u>behaviour and conduct disorders in children and young people²</u>. [2018]
- 1.5.8 If after an ADHD-focused group parent-training programme, ADHD
 symptoms are still causing severe impairment across more than one
 domain in a child under 5 years, obtain specialist advice (ideally from a
 tertiary service).

To find out why the committee made the 2018 recommendations on managing ADHD – children under 5 years and how they might affect practice, see <u>rationale and impact</u>.

11

12 Children and young people aged 5 years³ and over

- 131.5.9Offer parents and carers of all children and young people aged 5 years14and over with ADHD, group-based ADHD-focused support that includes15education and information on causes and impacts of ADHD and advice on16parenting strategies. This may be as few as 1 or 2 sessions and should17include both parents and carers if feasible. [2018]
- 181.5.10Offer medication for children and young people with ADHD aged 5 years19and over if their ADHD symptoms are having a persistent significant20impact in at least one domain of their everyday life after environmental21modifications. See the recommendations on medication choice. [2018]

² It should be noted that this does not imply that all children under 5 years with ADHD have antisocial behaviour or a conduct disorder but that the same general principles of care apply.
² At the time of consultation (September 2017), medicines used for the treatment of ADHD did not have a UK marketing authorisation for use in children aged 5 years and under for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

1	1.5.11	If a child or young person aged 5 years or over has ADHD and symptoms
2		of oppositional defiant disorder or conduct disorder, offer parents and
3		carers a parent-training programme in line with recommendations 1.5.1 to
4		1.5.10 in NICE's guideline on antisocial behaviour and conduct disorders
5		in children and young people as well as group-based ADHD-focused
6		support. [2018]
7	1.5.12	Consider a course of cognitive behavioural therapy (CBT) for young
8		people with ADHD who have benefited from medication but whose
9		symptoms continue to have a significant impact on at least one domain of
10		their everyday life, addressing the following areas:
11		 social skills with peers
12		problem-solving
13		self-control
14		active listening skills
15		 dealing with and expressing feelings. [2018]
16	1.5.13	Consider individual parent-training/education programmes for parents and
17		carers of children and young people with ADHD when:
18		there are particular difficulties for families in attending group sessions
19		[for example, because of disability, needs related to diversity such as
20		language differences, learning disability (intellectual disability), parental
21		ill-health, problems with transport, or where other factors suggest poor
22		prospects for therapeutic engagement]
23		 a family's needs are too complex to be met by group-based parent-
24		training/education programmes. [2018]

To find out why the committee made the 2018 recommendations on managing ADHD – children and young people aged 5 years and over, and how they might affect practice, see <u>rationale and impact</u>

25

1 **Adults** 2 1.5.14 Offer medication to adults with ADHD if their ADHD symptoms are having 3 a significant impact on at least one domain of their everyday life after 4 environmental modifications. See the recommendations on medication 5 choice. [2018] 1.5.15 Consider non-pharmacological treatment for adults with ADHD who have: 6 7 made an informed choice not to have medication 8 difficulty adhering to medication 9 found medication to be ineffective or cannot tolerate it. [2018] 1.5.16 10 Consider non-pharmacological treatment in combination with medication 11 for adults with ADHD who have benefited from medication but whose 12 symptoms continue to have a significant impact on at least one domain of 13 their everyday life. [2018] 14 1.5.17 When non-pharmacological treatment is indicated for adults with ADHD, 15 offer the following as a minimum: 16 a structured supportive psychological intervention focused on ADHD 17 regular follow-up either in person or by phone. 18 Treatment may involve elements of or a full course of CBT. [2018] To find out why the committee made the 2018 recommendations on managing ADHD – adults and how they might affect practice, see rationale and impact 19

20 1.6 Dietary advice

21	1.6.1	Healthcare professionals should stress the value of a balanced diet, good
22		nutrition and regular exercise for children, young people and adults with
23		ADHD. [2008]

1 2 3	1.6.2	Do not advise elimination of artificial colouring and additives from the diet as a generally applicable treatment for children and young people with ADHD. [2016]
4 5	1.6.3	Ask about foods or drinks that appear to influence hyperactive behaviour as part of the clinical assessment of ADHD in children and young people,
6		and:
7 8 9 10 11 12 13 14		 if there is a clear link, advise parents or carers to keep a diary of food and drinks taken and ADHD behaviour if the diary supports a relationship between specific foods and drinks and behaviour, offer referral to a dietitian ensure that further management (for example, specific dietary elimination) is jointly undertaken by the dietitian, mental health specialist or paediatrician, and the parent or carer and child or young person. [2016]
15 16	1.6.4	Do not advise or offer dietary fatty acid supplementation for treating ADHD in children and young people. [2016]
17 18 19 20	1.6.5	Advise the family members or carers of children with ADHD that there is no evidence about the long-term effectiveness or potential harms of a 'few food' diet for children with ADHD, and only limited evidence of short-term benefits. [2016]
21	1.7	Medication
22 23 24	1.7.1	Use this guideline with the NICE guideline on <u>medicines optimisation: the</u> <u>safe and effective use of medicines to enable the best possible outcomes.</u> [2018]
25	Baseline	assessment
26 27	1.7.2	Before starting medication, people with ADHD should have a full assessment, which should include:
28 29		 a review to confirm they continue to meet the criteria for ADHD and need treatment

1		 a review of mental health and social circumstances, including:
2		 presence of coexisting mental health and neurodevelopmental
3		conditions
4		 current educational or employment circumstances
5		 risk assessment for substance misuse and drug diversion
6		 care needs
7		 a review of physical health, including:
8		 a medical history, taking into account conditions that may be
9		contraindications for specific medicines
10		 current medication
11		 height and weight (measured and recorded against the normal range
12		for age, height and sex)
13		 baseline pulse and blood pressure (measured with an appropriately
14		sized cuff and compared with the normal range for age)
15		 an ECG if the treatment may affect the QT interval (for example,
16		tricyclics and monoamine oxidase inhibitors). [2018]
17	1.7.3	Refer for a cardiology opinion before starting medication for ADHD if any
18		of the following apply:
19		 history of congenital heart disease or previous cardiac surgery
20		
A 1		 history of sudden death in a first-degree relative under 40 years, which
21		 history of sudden death in a first-degree relative under 40 years, which could suggest a family history of cardiomyopathy or channelopathy
21 22		
		could suggest a family history of cardiomyopathy or channelopathy
22		could suggest a family history of cardiomyopathy or channelopathyshortness of breath on exertion compared with peers
22 23		 could suggest a family history of cardiomyopathy or channelopathy shortness of breath on exertion compared with peers fainting on exertion or in response to fright or noise
22 23 24		 could suggest a family history of cardiomyopathy or channelopathy shortness of breath on exertion compared with peers fainting on exertion or in response to fright or noise palpitations that are rapid, regular and start and stop suddenly (fleeting
22 23 24 25		 could suggest a family history of cardiomyopathy or channelopathy shortness of breath on exertion compared with peers fainting on exertion or in response to fright or noise palpitations that are rapid, regular and start and stop suddenly (fleeting occasional bumps are usually ectopic and do not need investigation)
22 23 24 25 26		 could suggest a family history of cardiomyopathy or channelopathy shortness of breath on exertion compared with peers fainting on exertion or in response to fright or noise palpitations that are rapid, regular and start and stop suddenly (fleeting occasional bumps are usually ectopic and do not need investigation) chest pain suggesting cardiac origin

To find out why the committee made the 2018 recommendations on medication -

baseline assessment and how they might affect practice, see rationale and impact.

1

2 Medication choice – children aged 5 years and over and young people

- 3 Recommendations 1.7.4 to 1.7.7 update NICE's technology appraisal guidance on
- 4 methylphenidate, atomoxetine and dexamfetamine for ADHD in children and
- 5 adolescents (TA98).
- 6 1.7.4 Offer methylphenidate as first-line pharmacological treatment for children
 7 aged 5 years⁴ and over and young people with ADHD. [2018]
- 8 1.7.5 Consider lisdexamfetamine for children aged 5 years⁵ and over and young
 9 people whose ADHD symptoms are not responding adequately to
 10 methylphenidate. [2018]
- 111.7.6Consider dexamfetamine⁶ for children aged 5 years and over and young12people whose ADHD symptoms are responding to lisdexamfetamine but13who cannot tolerate the longer effect profile. [2018]
- 14 1.7.7 Offer atomoxetine or guanfacine to children aged 5 years⁷ and over and
 15 young people if:

⁴ At the time of consultation (September 2017), methylphenidate did not have a UK marketing authorisation for this indication in children aged 5 years or under. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's <u>Prescribing guidance: prescribing unlicensed medicines</u> for further information.

⁵ At the time of consultation (September 2017) lisdexamfetamine did not have a UK marketing authorisation for this indication in children aged 5 years or under. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's <u>Prescribing guidance: prescribing unlicensed medicines</u> for further information.

⁶ 'At the time of consultation (September 2017) dexamfetamine was only licensed for the treatment of ADHD in children and adolescents aged 6 to 17 years when response to previous methylphenidate treatment is considered clinically inadequate. Dexamfetamine is not licensed for the treatment of ADHD in children and adolescents aged 5 to 17 years who have responded to, but are intolerant to lisdexamfetamine. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's <u>Prescribing guidance: prescribing unlicensed medicines</u> for further information.

⁷ At the time of consultation (September 2017) atomoxetine or guanfacine did not have a UK marketing authorisation for this indication in children aged 5 years. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be

1 2 3 4		 they cannot tolerate methylphenidate or lisdexamfetamine, or their symptoms have not responded to separate 6-week trials of lisdexamfetamine and methylphenidate, having tried alternative formulations and adequate doses. [2018]
5	Medicatio	on choice – adults
6 7	1.7.8	Offer lisdexamfetamine ⁸ as first-line pharmacological treatment for adults with ADHD. [2018]
8 9	1.7.9	Consider methylphenidate ⁹ for adults whose ADHD symptoms are not responding adequately to lisdexamfetamine. [2018]
10 11 12	1.7.10	Consider dexamfetamine ¹⁰ for adults whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile. [2018]
13	1.7.11	Offer atomoxetine ¹¹ to adults if:
14 15 16 17		 they cannot tolerate lisdexamfetamine or methylphenidate, or their symptoms have not responded to separate 6-week trials of lisdexamfetamine and methylphenidate, having considered alternative formulations and doses [2018]
17		formulations and doses. [2018]

obtained and documented. See the General Medical Council's <u>Prescribing guidance: prescribing</u> <u>unlicensed medicines</u> for further information.

⁸ At the time of consultation (September 2017) lisdexamfetamine was licensed for use in adults with symptoms of ADHD that pre-existed in childhood. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information

⁹ At the time of consultation (September 2017) methylphenidate did not have a UK marketing authorisation for this indication in adults. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's <u>Prescribing guidance: prescribing unlicensed medicines</u> for further information.

¹⁰ At the time of consultation (September 2017) dexamfetamine did not have a UK marketing authorisation for this indication in adults. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's <u>Prescribing guidance</u>: <u>prescribing unlicensed medicines</u> for further information.

¹¹ At the time of consultation (September 2017) atomoxetine was licensed for use in adults with symptoms of ADHD that pre-existed in childhood. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.


To find out why the committee made the 2018 recommendations on medication – choice and how they might affect practice, see <u>rationale and impact</u>.

1

2	General	prescribing information
3	1.7.12	Obtain a second opinion or refer to tertiary services if ADHD symptoms in
4		a child aged 5 years or over, a young person or adult are unresponsive to
5		one or more stimulants and one non-stimulant. [2018]
6	1.7.13	Do not offer any medication for ADHD other than in recommendations
7		1.7.4 to 1.7.11 outside a specialist (tertiary) ADHD service (for example,
8		guanfacine ¹² for adults, clonidine ¹³ for children with ADHD and sleep
9		disturbance, rages or tics). [2018]
10	1.7.14	Offer the same medication choices to children aged 5 years and over,
11		young people and adults with ADHD who have an anxiety disorder, tic
12		disorder or autism spectrum disorder as other people with ADHD. [2018]
13	1.7.15	Do not offer immediate-release stimulants or modified-release stimulants
14		that can be easily injected or insufflated if there is a risk of stimulant
15		misuse or diversion. [2018]
16	1.7.16	Be cautious about prescribing stimulants for ADHD if there is a risk of
17		stimulant diversion for cognitive enhancement or appetite suppression.
18		[2018]
19	1.7.17	For children aged 5 years and over, young people and adults with ADHD
20		experiencing an acute psychotic or manic episode:

¹² At the time of consultation (September 2017) guanfacine did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's <u>Prescribing guidance: prescribing unlicensed medicines</u> for further information

¹³ At the time of consultation (September 2017) clonidine did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's <u>Prescribing guidance: prescribing unlicensed medicines</u> for further information.



¹⁴ At the time of consultation (September 2017) risperidone did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's <u>Prescribing guidance: prescribing unlicensed medicines</u> for further information

1 2		 physical health conditions (for example, epilepsy or acquired brain injury). [2018]
3	1.7.22	During the titration phase, symptoms and side effects should be recorded
4		at baseline and at each dose change on standard scales (for example,
5		Conners' 10-item scale) by parents and teachers and progress reviewed
6		regularly (for example, by weekly telephone contact) with a specialist.
7		[2018]
8	1.7.23	Titrate the dose against symptoms and side effects in line with the BNF
9		until dose optimisation is achieved, that is, reduced symptoms, positive
10		behaviour change, improvements in education, employment and
11		relationships, with tolerable side effects. [2018]
12	1.7.24	After titration and dose stabilisation, prescribing and monitoring should be
13		carried out under shared care arrangements with primary care. [2018]
14	1.7.25	When prescribing stimulants for ADHD, think about modified-release
15		once-daily preparations for the following reasons:
16		convenience
17		improving adherence
18		reducing stigma (because there is no need to take medication at school
19		or in the workplace)
20		 reducing problems of storing and administering controlled drugs at
21		school
22		 the risk of stimulant misuse and diversion with immediate-release
23		preparations
24		 their pharmacokinetic profiles.
25		Immediate-release preparations may be suitable if more flexible dosing
26		regimens are needed, or during initial titration to determine correct dosing
27		levels. [2018]
28	1.7.26	Think about using immediate- and modified-release preparations of the
29		same treatment to optimise effect (for example, a modified-release

1		preparation of methylphenidate in the morning and an immediate-release
2		preparation of methylphenidate at another time of the day to extend the
3		duration of effect). [2018]
4	1.7.27	Be aware that individuals respond to stimulants in different ways in terms
5		of size of effects, duration of action and adverse effects. [2018]
	To find o	out why the committee made the 2018 recommendations on medication –
	initiation	and titration, and how they might affect practice, see rationale and impact.
6		
7	1.8	Follow-up and monitoring
8	1.8.1	Monitor side effects resulting from medication for ADHD and document in
9		the person's notes. [2018]
10	1.8.2	Consider using standard symptom and side effect rating scales for clinical
11		assessment and throughout the course of treatment for people with
12		ADHD. [2018]
13	1.8.3	Ensure that children, young people and adults receiving treatment for
14		ADHD have review and follow-up according to the severity of their
15		condition, regardless of whether or not they are taking medication. [2018]
16	Height a	ind weight
17	1.8.4	For people taking medication for ADHD:
18		 measure height every 6 months in children and young people
19		 measure weight 3 and 6 months after starting treatment and every
20		6 months thereafter, or more often if concerns arise
21		 plot height and weight of children and young people on a growth chart
22		and ensure review by the healthcare professional responsible for
23		treatment. [2018]
24	1.8.5	Consider monitoring body mass index of adults with ADHD if there has
25		been weight change as a result of their treatment, and changing the
26		medication if weight change persists. [2018]

1	1.8.6	If weight loss is a clinical concern consider the following strategies:
2		• taking medication either with or after food, rather than before meals
3		 taking additional meals or snacks early in the morning or late in the
4		evening when stimulant effects have worn off
5		obtaining dietary advice
6		 consuming high-calorie foods of good nutritional value
7		a planned break in treatment. [2018]
8	1.8.7	If a child or young person's height or weight over time is significantly
9		affected by medication (that is, they have not met the height expected for
10		their age), consider a planned break in treatment over school holidays to
11		allow 'catch-up' growth. [2018]
12	Cardiova	scular
13	1.8.8	Monitor heart rate and blood pressure and compare with the normal range
14		for age before and after each dose change and every 6 months. [2018]
15	1.8.9	Do not offer routine blood tests (including liver function tests) or ECGs to
16		people taking medication for ADHD unless there is a clinical indication.
17		[2018]
18	1.8.10	If a person taking ADHD medication has sustained resting tachycardia
19		(more than 120 beats per minute), arrhythmia or systolic blood pressure
20		greater than the 95th percentile (or a clinically significant increase)
21		measured on 2 occasions, reduce their dose and refer them to a
22		paediatric cardiologist or adult physician. [2018]
23	1.8.11	If a person taking guanfacine has sustained orthostatic hypotension or
24		fainting episodes, reduce their dose or switch to another ADHD
25		medication. [2018]
26	Tics	
27	1.8.12	If a person taking stimulants develops tics, think about whether:
28		• the tics are related to the stimulant (tics naturally wax and wane) and

- the impairment associated with the tics outweighs the benefits of ADHD
 treatment.
- 3 If tics are stimulant related, reduce the stimulant dose, or consider
- 4 changing to guanfacine (in children aged 5 years and over and young
- 5 people only), atomoxetine¹⁵ or adding clonidine¹⁶ or stopping medication.
- 6 **[2018]**

7 Sexual dysfunction

8 1.8.13 Monitor young people and adults with ADHD for sexual dysfunction (that
9 is, erectile and ejaculatory dysfunction) and dysmenorrhoea as potential
10 side effects of atomoxetine. [2018]

11 Seizures

121.8.14If a person with ADHD develops new seizures or a worsening of existing13seizures, review their ADHD medication and stop any medication that14might be contributing to the seizures. After investigation cautiously15reintroduce ADHD medication if it is unlikely to be the cause of the16seizures. [2018]

17 Sleep

181.8.15Monitor changes in sleep pattern (for example, with a sleep diary) and19adjust medication accordingly. [2018]

20 Worsening behaviour

211.8.16Monitor the behavioural response to medication, and if behaviour worsens22adjust medication and review the diagnosis. [2018]

¹⁵ At the time of consultation (September 2017) atomoxetine was licensed for use in adults with symptoms of ADHD that pre-existed in childhood. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

¹⁶ At the time of consultation (September 2017) clonidine did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's <u>Prescribing guidance: prescribing unlicensed medicines</u> for further information.

1 Stimulant diversion

1.8.17 Healthcare professionals and parents or carers should monitor changes in
 the potential for stimulant misuse and diversion, which may come with
 changes in circumstances and age. [2018]

To find out why the committee made the 2018 recommendations on medication – monitoring side effects, and how they might affect practice, see <u>rationale and impact</u>.

5

6	1.9	Adherence to treatment
7	1.9.1	Use this guideline with the NICE guideline on medicines adherence to
8		improve the care for adults with ADHD. The principles also apply to
9		children and young people. [2018]
10	1.9.2	Be aware that the symptoms of ADHD may lead to people having difficulty
11		adhering to treatment plans (for example, remembering to order and
12		collect medication). [2018]
13	1.9.3	Ensure that people are fully informed of the balance of risks and benefits
14		of any treatment for ADHD and check that problems with adherence are
15		not due to misconceptions (for example, tell people that medication does
16		not change personality). [2018]
17	1.9.4	Encourage the person with ADHD to use the following strategies to
18		support adherence to treatment:
19		being responsible for their own health, including taking their medication
20		as needed
21		 following clear instructions about how to take the medication in picture
22		or written format, which may include information on dose, duration, side
23		effects, dosage schedule (the instructions should stay with the
24		medication, for example, a sticker on the side of the packet)
25		 using visual reminders to take medication regularly (for example, apps,
26		alarms, clocks, pill dispensers, or notes on calendars or fridges)

1		 taking medication as part of their daily routine (for example, before
2		meals or after brushing teeth)
3		 attending peer support groups (for both the person with ADHD and for
4		the families and carers). [2018]
5	1.9.5	Encourage parents and carers to oversee ADHD medication for children
6		and young people. [2018]
7	Supporti	ng families in which a parent has ADHD
8	1.9.6	Think about the needs of a parent with ADHD, including whether they
9		need extra support with organisational strategies to help a child with
10		ADHD to take their medication as prescribed. [2018]
11	Supporti	ng adherence to non-pharmacological treatments
12	1.9.7	Support adherence to non-pharmacological treatments (for example,
13		CBT) by discussing the following:
14		• the balance of risks and benefits (for example, how the treatment can
15		have a positive effect on ADHD symptoms)
16		 the potential barriers to continuing treatment, including:
17		 not being sure if it is making any difference
18		 the time and organisational skills needed to commit to the treatment
19 20		 the time that might be needed outside of the sessions (for example,
20		to complete homework)
21		• strategies to deal with any identified barriers (for example, scheduling
22		sessions to minimise inconvenience or seeking courses with child care
23		provision)
24		a possible effect of treatment being increased self-awareness and the
25		challenging impact this may have on the person and the people around
26		them
27		 the importance of long-term adherence beyond the duration of any
28		initial programme (for example, by attending follow-up/refresher support
29		to sustain learned strategies). [2018]

To find out why the committee made the 2018 recommendations on adherence to

treatment and how they might affect practice, see rationale and impact.

1

2	1.10	Review of medication and discontinuation
3	1.10.1	An ADHD specialist should review ADHD medication at least once a year
4		and discuss with the person with ADHD (and their families and carers as
5		appropriate) whether medication should be continued. The review should
6		include a comprehensive assessment of the:
7		 preference of the child, young person or adult with ADHD (and their
8		family or carers as appropriate)
9		 benefits, including how well the current treatment is working
10		side effects
11		 clinical need and whether drug optimisation has been achieved
12		 impact on education and employment
13		 effects of missed doses, planned dose reductions and periods of no
14		treatment
15		 effect of medication on existing or new mental health, physical health or
16		neurodevelopmental conditions
17		 need for and type of support required (for example, psychological,
18		educational, social support) if medication has been optimised but
19		ADHD symptoms continue to have a significant impact. [2018]
20	1.10.2	Encourage people with ADHD to discuss any preferences to stop or
21		change medication and to be involved in any decisions about stopping
22		treatments. [2018]
23	1.10.3	Consider trial periods of stopping medication or reducing the dose when
24		assessment of the overall balance of benefits and harms suggests this
25		may be appropriate. [2018]

To find out why the committee made the 2018 recommendations on review of medication and discontinuation, and how they might affect practice, see <u>rationale</u> and <u>impact</u>.

1 Terms used in this guideline

2 Environmental modifications

- 3 Changes that are made to the physical environment, for example, changes to
- 4 seating arrangements at school, changes to lighting and to noise.

5 **Recommendations for research**

6 The guideline committee has made the following recommendations for research.

7 **1** Children and young people aged 5 to 18 years – brief, group-

8 based, ADHD-focused, parent-training intervention

- 9 What is the clinical and cost effectiveness, and optimum length of a brief parent-
- 10 training intervention for parents and carers of children and young people with ADHD
- 11 aged 5 to 18 years?

12 Why this is important

- 13 The evidence identified in this guideline was not clear about the benefit of formal
- 14 parent-training programmes for children and young people aged 5 to 18 years. This
- 15 guideline was unable to provide a robust assessment of the cost effectiveness of an
- 16 intervention , partly because of uncertainty over the number of sessions/length of
- 17 intervention needed to achieve the clinical benefits seen in trials. This research
- 18 recommendation would help address these uncertainties.

19 **2** Medication choice in people with coexisting conditions

- 20 What is the clinical and cost effectiveness of ADHD medications in people with
- 21 ADHD and tic disorders, a history of psychosis or mania, or emotional dysregulation?

22 Why is this important

- 23 This guideline did not identify any evidence to justify different medication choices in
- the groups with ADHD and tic disorders, a history of psychosis or mania, or
- 25 emotional dysregulation. These groups are often excluded from trials. There are
- reasons (for example, mechanism of action of medication options, previous reports
- 27 of adverse events) to suspect that these groups may respond differently to different

- 1 drugs but a lack of trials to confirm this. Primarily there are some concerns that
- 2 stimulant medication may worsen the symptoms of any of these coexisting
- 3 conditions and therefore non-stimulant medication should be preferred.

4 **3** Medication choice in people with no previous medication for

5 **ADHD**

- 6 What is the clinical and cost effectiveness of ADHD medications in people with
- 7 ADHD with no previous medication for the condition?

8 Why is this important

- 9 This guideline makes recommendations for the medication choices for people with
- 10 ADHD, but most of the evidence to support these recommendations comes from
- 11 studies in people who have previously received medication. Therefore, these studies
- 12 often include a population not representative of the people with newly diagnosed
- 13 ADHD. There may be differing levels of efficacy of the various treatment options in
- 14 this population.

15 **4** *Prescribing beyond monotherapy*

- 16 What is the clinical and cost effectiveness of various ADHD prescribing strategies
- 17 when monotherapy has failed?
- 18 Why is this important
- 19 This guideline makes recommendations for the medication choices for people with
- 20 ADHD up to the point at which common monotherapies are exhausted. There is very
- 21 little evidence to guide healthcare professionals beyond this point, particularly with
- regards to whether there is a benefit of prescribing stimulant and non-stimulant
- 23 medication together.

24 **5** Children under 5 years – brief, group-based, ADHD-focused,

25 parent-training intervention

- 26 What is the clinical and cost effectiveness of pharmacological versus non-
- 27 pharmacological treatment versus a combination in children under 5 years with
- 28 ADHD?

1 Why is this important

- 2 Many children are diagnosed with ADHD under the age of 5 years. There is much
- 3 hesitancy around the use of ADHD medication in this age group, although there has
- 4 been little research into the option. There is more evidence in this age group
- 5 supporting the efficacy of non-pharmacological interventions (for example parent-
- 6 training programmes), but there is no evidence directly comparing the efficacy of this
- 7 with pharmacological treatment or a combination of the two.

8 Rationale and impact

9 **Recognition**

10 The committee's full discussion is in <u>evidence review A: risk factors.</u>

11 Why the committee made the 2018 recommendations

12 Evidence showed that the prevalence of ADHD is higher in some groups than in the 13 general population. The committee agreed that a recommendation was needed to 14 raise awareness of these groups among non-specialists to help them avoid missing a diagnosis of ADHD. Although no evidence was identified for a higher prevalence in 15 16 people within the secure estate and people with acquired brain injury, the committee 17 agreed that in their experience these groups often receive a late diagnosis of ADHD 18 or a misdiagnosis. No evidence was found on the increased risk of missing a 19 diagnosis of ADHD in girls. But the committee discussed the different symptoms 20 often found in this group, and agreed to make a recommendation to raise 21 awareness.

22 How the 2018 recommendations might affect practice

- 23 The recommendations are to raise awareness among non-specialists of a possible
- 24 diagnosis of ADHD in groups of people that they are already seeing. The
- 25 recommendations may increase the rates of diagnosis and referral for ADHD, but
- 26 these should be accurate and therefore appropriate diagnoses and management.

27 Information and support

28 The committee's full discussion is in <u>evidence review B: information and support.</u>

1 Why the committee made the 2018 recommendations

2 Good information and support tailored to need and circumstances are important for

- 3 all people using NHS services, but some aspects are particularly important for
- 4 people with ADHD. Evidence identified the need for information tailored to family
- 5 circumstances, particularly when a child has ADHD, and to highlight the importance
- 6 of daily structure for adults with ADHD.
- Evidence showed the importance of discussing key areas following a diagnosis of
 ADHD, particularly the positive impacts of receiving a diagnosis, such as improving
 understanding of symptoms. The committee used the evidence and their experience
 to agree other areas for discussion, including driving and possible issues with
- education and employment. They noted that schools and colleges may sometimes
- 12 question a diagnosis of ADHD and not understand how symptoms can affect daily
- 13 functioning. In addition, healthcare professionals treating a coexisting condition may
- 14 not be aware of how ADHD symptoms may affect behaviour (organisation and time
- 15 management) and adherence to treatment.
- 16 There was evidence that parents of children with ADHD often feel a sense of
- 17 isolation when attending parent-training programmes. The committee agreed that
- 18 healthcare professionals should explain to parents that an invitation to attend a
- 19 parent-training programme does not imply bad parenting.
- 20 In the committee's experience, people who are assessed for ADHD but not given a
- 21 formal diagnosis are a neglected group who would benefit from advice on where to
- 22 get support for troublesome symptoms.

23 How the 2018 recommendations might affect practice

- 24 The recommendations should reflect good current practice. Healthcare professionals
- 25 may spend more time discussing the potential impacts of a diagnosis, but this is
- 26 likely to mean improved quality of life for the person with ADHD and better
- 27 management of their symptoms.

28 *Managing ADHD – planning treatment*

29 The committee's full discussion is in evidence review H: managing treatment.

1 Why the committee made the 2018 recommendations

Evidence showed the importance of joint decision-making when planning treatment;
particularly important was the discussion before starting treatment. This was also the
committee's experience and they recommended that these discussions should be

5 repeated throughout care.

The committee recommended key areas highlighted in the evidence that should be
discussed with the person and their family before starting treatment. This included
the benefits and harms of medications and consideration of these alongside other
treatment choices.

- 10 In the committee's experience, other mental health and neurodevelopmental
- 11 conditions may affect treatment choices and how successful these are. The
- 12 committee emphasised the importance of a holistic approach to managing ADHD.

13 Evidence indicated that parents and carers of children with ADHD found it hard to

- 14 make decisions about treatment and wanted time to think about the effect of any
- 15 environmental modifications. The committee recognised the importance of having
- 16 the opportunity to regularly revisit and discuss earlier decisions and so
- 17 recommended that healthcare professionals remind people that they can do this if
- 18 they wish.

19 The committee acknowledged that it is important to include children and young 20 people in any treatment discussions and recommended they should be encouraged 21 to say how they feel. This should include their views on the aims and effect of any 22 treatments. Healthcare professionals should be aware that these will change as the 23 child matures and will need revisiting. The committee also recognised that it was 24 important that young people and adults should have as much support as they need and should be asked if they would like someone to join discussions about treatment. 25 26 Decisions around treatment can have many influences, including teachers, peers 27 and the media.

- 28 Evidence identified concerns around lack of follow-up and the opportunity to review
- 29 medication choices and this was supported by the committee's experience. They
- 30 agreed that a yearly review with an ADHD specialist should be a comprehensive

- 1 assessment that revisits the areas discussed when starting treatment but also the
- 2 effect of current treatment. This would ensure that decisions around continuing or
- 3 stopping treatment are fully informed.

4 How the 2018 recommendations might affect practice

- 5 The recommendations should reflect good current practice. Where practice might
- 6 change, it is predominantly the approach to care that will be affected.

7 Managing ADHD – children under 5 years

- 8 The committee's full discussion is in evidence review E: non-pharmacological
- 9 efficacy and adverse events and evidence review F: combination treatment.

10 Why the committee made the 2018 recommendations

- 11 Evidence showed a clinically important benefit of an ADHD-focused group parent-
- 12 training programme for children under 5 years. There was limited evidence on the
- 13 efficacy of medication and because of concerns about medication in very young
- 14 children the committee agreed to recommend a group-based parent-training
- 15 programme as first-line treatment. However, the committee acknowledged that some
- 16 children may still have severe impairment after the programme. For these children,
- 17 the committee drew on their experience to recommend that healthcare professionals
- 18 should seek specialist advice, ideally from a tertiary service.

19 How the 2018 recommendations might affect practice

20 The recommendations reflect good current practice.

21 Managing ADHD – children and young people aged 5 years and

22 **over**

- 23 The committee's full discussion is in evidence review E: non-pharmacological
- 24 efficacy and adverse events and evidence review F: combination treatment.

- 26 Evidence indicated that all parents and carers of children and young people aged
- 5 years and over would benefit from group support. After discussion of current good
- 28 practice and consideration of the balance of benefits and costs, the committee
- 29 decided to recommend limited group-based ADHD-focused support (may be as few

as 1 or 2 sessions) for parents and carers of all children and young people with
 ADHD.

- Evidence showed the benefit of medication in this age group and this was in line with the committee's experience. Medication offered a good balance of benefits and costs so the committee agreed to recommend it when ADHD symptoms are having a significant impact on at least one domain of everyday life despite environmental
- 7 modifications.
- 8 Combining a full parent-training programme with medication did not offer a good
- 9 balance of benefits and costs for all children and young people in this age group so
- 10 the committee decided to not to make a recommendation on this.
- 11 Some evidence showed a benefit of cognitive-behavioural therapy (CBT) in young
- 12 people with ADHD. The committee agreed that this should be considered when a
- 13 young person has benefited from medication but still have symptoms that are having
- 14 a significant impact on their lives. They used their experience to recommend areas
- 15 that a programme should address.

16 How the 2018 recommendations might affect practice

- 17 Children aged 5 years and over and young people are only offered medication if
- 18 symptoms are having a significant impact in at least one domain of their everyday life
- 19 despite environmental modifications. This may be a slightly different group from
- 20 those with severe ADHD who were offered medication in the 2008 recommendation.
- 21 But there is considerable overlap, and the 2018 recommendation is unlikely to result
- in a substantial increase in prescribing and resource use.

23 Managing ADHD – adults

- 24 The committee's full discussion is in evidence review E: non-pharmacological
- 25 efficacy and adverse events and evidence review F: combination treatment.

- 27 Evidence directly comparing medication with non-pharmacological treatment
- supported the use of medication for first-line treatment of ADHD in adults. This was
- 29 in line with the committee's experience so they agreed to recommend medication

- 1 when ADHD symptoms are having a significant impact on at least one domain of
- 2 everyday life despite environmental modifications.

3 Evidence indicated a benefit of non-pharmacological treatment, although this was 4 less than for medication. There was also evidence of the importance of offering a 5 choice of treatments so the committee agreed that non-pharmacological treatment 6 should be considered for adults who have made an informed choice not to have 7 medication, have difficulty adhering to medication or have found medication 8 ineffective or intolerable. Based on their experience, the committee recommended 9 that the treatment may include elements or a full programme of CBT and should 10 include a structured supportive psychological intervention focused on ADHD, with 11 regular follow-up and information.

- 12 Combining medication with non-pharmacological treatment did not offer the best
- 13 balance of benefits and costs so the committee decided that combination treatment
- 14 should only be considered when medication has offered some benefit but symptoms
- 15 continue to have a significant effect on everyday life.
- 16 How the 2018 recommendations might affect practice
- 17 The recommendations reflect good current practice.

18 Medication – baseline assessment

19 The committee's full discussion is in <u>evidence review D: pharmacological safety.</u>

20 Why the committee made the 2018 recommendations

- 21 The committee noted that it is important to carry out a baseline assessment before
- 22 starting ADHD medication. Evidence was limited on what should be assessed
- 23 clinically, but the committee used their experience and expert advice to recommend
- 24 a general review of health and social circumstances, and a review of physical health,
- 25 including an ECG, depending on the proposed treatment. The committee used their
- 26 experience to outline criteria for referral for a cardiologist opinion.

27 How the 2018 recommendations might affect practice

28 The recommendations reflect good current practice.

1 Medication – choice

2 The committee's full discussion is in evidence review C: pharmacological efficacy

3 and sequencing.

4 Why the committee made the 2018 recommendations

5 Evidence showed a clinically important benefit for monotherapy with the stimulants methylphenidate and lisdexamfetamine compared with placebo or other drugs. This 6 7 was supported by the committee's experience that stimulants work guicker than non-8 stimulant drugs (for example, atomoxetine and guanfacine), which can take up to 2 9 weeks to have an effect. The committee used the evidence, their experience and the 10 drug licensing to recommend methylphenidate as a first treatment for children aged 11 5 years and over and young people, and lisdexamfetamine as a first treatment for 12 adults.

13 The committee acknowledged the rising cost of dexamfetamine and agreed that it 14 should only be considered when lisdexamfetamine is effective but the longer effect 15 profile is not well tolerated.

16 The committee agreed that if an initial stimulant has not been effective then another

17 should be considered. This would be lisdexamfetamine for children aged 5 years and

18 over and young people, and methylphenidate for adults. The committee

19 acknowledged that these recommendations were outside the licensing indications,

20 but based their decision on the evidence and their clinical experience that stimulants

21 are more effective than non-stimulants.

22 Atomoxetine and guanfacine were the non-stimulant drugs with the most convincing 23 evidence. The committee noted that atomoxetine is more widely used and that there 24 was stronger evidence for a benefit of atomoxetine compared with placebo than 25 guanfacine compared with placebo. One trial directly comparing atomoxetine with guanfacine generally showed a clinically important benefit of guanfacine. Taking into 26 27 account the licensing status of these drugs and the familiarity of most healthcare 28 professionals with them, the committee recommended that in children aged 5 years 29 and over and young people either drug could be offered after intolerance or a lack of 30 response to stimulants (methylphenidate and lisdexamfetamine). As guanfacine is 31 not licensed for use in adults and there was no evidence specifically supporting its

- 1 use in this population, the committee recommended atomoxetine for adults with
- 2 intolerance or a lack of response to stimulants.
- 3 There was not enough evidence to justify specific recommendations for other drugs
- 4 so the committee recommended that after at least one stimulant and non-stimulant
- 5 had been tried, healthcare professionals should obtain a second opinion or refer to a
- 6 tertiary service.

7 Medication choice for people with coexisting conditions

- 8 There was very little evidence on medication choice for people with ADHD and
- 9 coexisting conditions and so the committee made research recommendations to
- 10 address this gap. The committee agreed that neither the available evidence nor their
- 11 experience justified a different choice of ADHD medication for people with ADHD
- 12 and coexisting conditions, but there should be slower titration, more careful
- 13 monitoring and recording of side effects, and regular weekly contact. However, the
- 14 committee recommended that ADHD medication should be stopped in people
- 15 experiencing a psychotic episode because they agreed that ADHD medication could
- 16 worsen psychotic symptoms.

17 How the 2018 recommendations might affect practice

18 The recommendations reflect good current practice.

19 Medication – initiation and titration

20 The committee's full discussion is in evidence review D: pharmacological safety.

- 22 The committee discussed that the careful initiation of ADHD medication is key to a
- 23 successful treatment plan. This includes starting and titrating medication according
- 24 to the BNF and the person's tolerance until the dose is optimised (reduced
- 25 symptoms, positive behaviour change, improvements in education, employment and
- relationships and tolerable side effects). The committee agreed that healthcare
- 27 professionals should be aware of the pharmacokinetic profiles of ADHD medication
- 28 because preparations can vary in their profiles. This is important when considering
- 29 which medication or formulation to prescribe.

- 1 How the 2018 recommendations might affect practice
- 2 The recommendations reflect good current practice.

3 Medication – monitoring side effects

4 The committee's full discussion is in evidence review D: pharmacological safety.

5 Why the committee made the 2018 recommendations

- 6 Evidence showed clinically important differences in sleep disturbance, decreased
- 7 appetite and weight changes in people taking ADHD medication. In the committee's
- 8 experience these are some of the most troublesome side effects. Because of
- 9 concerns about decreased appetite and weight change, the committee advised that
- 10 weight should be checked at least every 6 months in children and young people and
- 11 body mass index should be monitored in adults. The committee recommended that
- 12 changes in sleep pattern should be recorded and medication adjusted accordingly.
- 13 There was some evidence that people on atomoxetine may experience sexual
- 14 dysfunction, in particular erectile dysfunction, and the committee agreed that this
- 15 should be monitored.

16 How the 2018 recommendations might affect practice

17 The committee noted that the recommendations will reinforce current best practice.

18 Adherence to treatment

19 The committee's full discussion is in <u>evidence review G: adherence.</u>

- 21 The evidence identified several factors that affect adherence to treatment and these
- 22 were supported by the committee's own experience.
- 23 The evidence highlighted time management and forgetfulness as particular issues so
- 24 the committee made a recommendation that healthcare professionals should be
- aware that people with ADHD may have problems remembering to order and collect
- 26 medication. The committee provided examples of how healthcare professionals
- 27 might encourage people to follow strategies that support adherence (for example,
- 28 following clear instructions and using visual reminders).

1 A common worry about treatment is that it might change personality and the

- 2 committee agreed that this could affect adherence to both medication and non-
- 3 pharmacological treatments. Misconceptions about the effects of treatment and
- 4 worries about side effects were common themes identified, and the committee
- 5 agreed that it was important that healthcare professionals address these.
- 6 Evidence identified the influence people close to a person with ADHD can have on
- 7 adherence. The committee agreed that it was important that while children and
- 8 young people should take responsibility for their own health (including taking
- 9 medication) parents and carers should oversee them. The committee discussed the
- 10 difficulties in families where parents may also have ADHD and made a
- 11 recommendation to remind healthcare professionals that these families may need
- 12 extra support.
- 13 The committee discussed that adherence to non-pharmacological treatment was an
- 14 important issue that was rarely addressed. They used their own experience to
- 15 recommend that healthcare professionals discuss the commitment, time and
- 16 organisational skills needed for successful adherence to non-pharmacological
- 17 treatment.

18 How the 2018 recommendations might affect practice

19 The committee noted that the recommendations will reinforce current best practice.

20 **Review of medication and discontinuation**

21 The committee's full discussion is in evidence review I: withdrawal and drug holidays.

- 23 Limited evidence showed possible worsening of ADHD symptoms on stopping
- 24 medication but supported a reduction in side effects after withdrawal. The committee
- 25 used their experience to make a recommendation on emphasising the importance of
- assessing the overall benefits and harms of medication as part of a review. The
- 27 committee agreed that it was important to highlight the elements of a medication
- review that are important for someone with ADHD; they based the elements on
- 29 evidence on adverse effects of medication, management of treatment, adherence
- 30 and information and support.

- 1 How the 2018 recommendations might affect practice
- 2 The committee noted that the recommendations will reinforce current best practice.

3 Putting this guideline into practice

4 [This section will be completed after consultation]

- 5 NICE has produced <u>tools and resources</u> to help you put this guideline into practice.
- 6 Putting recommendations into practice can take time. How long may vary from
- 7 guideline to guideline, and depends on how much change in practice or services is
- 8 needed. Implementing change is most effective when aligned with local priorities.
- 9 Changes recommended for clinical practice that can be done quickly like changes
- 10 in prescribing practice should be shared quickly. This is because healthcare
- 11 professionals should use guidelines to guide their work as is required by
- 12 professional regulating bodies such as the General Medical and Nursing and
- 13 Midwifery Councils.
- 14 Changes should be implemented as soon as possible, unless there is a good reason
- 15 for not doing so (for example, if it would be better value for money if a package of
- 16 recommendations were all implemented at once).
- 17 Different organisations may need different approaches to implementation, depending
- 18 on their size and function. Sometimes individual practitioners may be able to respond
- 19 to recommendations to improve their practice more quickly than large organisations.
- 20 Here are some pointers to help organisations put NICE guidelines into practice:
- 1. **Raise awareness** through routine communication channels, such as email or
- 22 newsletters, regular meetings, internal staff briefings and other communications with
- 23 all relevant partner organisations. Identify things staff can include in their own
- 24 practice straight away.
- 25 2. Identify a lead with an interest in the topic to champion the guideline and motivate
- 26 others to support its use and make service changes, and to find out any significant
- 27 issues locally.

3. Carry out a baseline assessment against the recommendations to find out
 whether there are gaps in current service provision.

4. Think about what data you need to measure improvement and plan how you
will collect it. You may want to work with other health and social care organisations
and specialist groups to compare current practice with the recommendations. This
may also help identify local issues that will slow or prevent implementation.

5. Develop an action plan, with the steps needed to put the guideline into practice,
and make sure it is ready as soon as possible. Big, complex changes may take
longer to implement, but some may be quick and easy to do. An action plan will help
in both cases.

6. For very big changes include milestones and a business case, which will set out
additional costs, savings and possible areas for disinvestment. A small project group
could develop the action plan. The group might include the guideline champion, a
senior organisational sponsor, staff involved in the associated services, finance and
information professionals.

- 7. Implement the action plan with oversight from the lead and the project group.
 Big projects may also need project management support.
- 8. Review and monitor how well the guideline is being implemented through the
 project group. Share progress with those involved in making improvements, as well
 as relevant boards and local partners.
- 21 NICE provides a comprehensive programme of support and resources to maximise
- 22 uptake and use of evidence and guidance. See our <u>into practice</u> pages for more
- 23 information.
- Also see Leng G, Moore V, Abraham S, editors (2014) Achieving high quality care practical experience from NICE. Chichester: Wiley.

26 **Context**

- 27 Attention deficit hyperactivity disorder (ADHD) is a heterogeneous disorder
- characterised by the core symptoms of hyperactivity, impulsivity and inattention,

1 which are judged excessive for the person's age or level of overall development. The 2 diagnosis is made on the basis of observed and reported behavioural symptoms. 3 Two main diagnostic systems are in current use, the International Classification of 4 Mental and Behavioural Disorders 10th revision (ICD-10) and the Diagnostic and 5 Statistical Manual of Mental Disorders 5th edition (DSM-5). Both systems require that symptoms are present in several settings such as school/work, home life and 6 7 leisure activities. Symptoms should be evident in early life, if only in retrospect; for 8 ICD-10, by age 7 years and for DSM-5 by age 12 years. ADHD may persist into adult 9 life.

10 Prevalence rates for ICD-10 (identifying hyperkinetic disorder) are 1 to 2% in

11 childhood. Under the previous, less stringent DSM-IV criteria, childhood prevalence

12 rates were 3 to 9% and these may increase under the new DSM-5 criteria.

13 The causes of ADHD are not fully understood but a number of risk factors are

14 associated with the condition. Genetic factors can have an influence with family

15 members frequently affected. The diagnosis of ADHD in older family members such

16 as parents may have previously been missed and should be considered.

17 Both the ICD-10 and DSM-5 require the presence of functional impairment due to symptoms of ADHD, with the symptoms adversely affecting psychological, social 18 19 and/or educational/occupational functioning. ADHD may vary considerably in its 20 severity, which is best judged by considering the level of impairment, pervasiveness, 21 and familial and social context. For some people, symptoms and impairment maybe 22 reduced through environmental modifications, such as a modified school curriculum 23 or choice of employment. ADHD is considered mild when symptoms are limited to 24 certain settings and causing mild impairment in a limited number of domains 25 (competencies such as completing schoolwork, work tasks, avoiding common hazards and forming positive interpersonal relationships). Moderate ADHD is present 26 27 when the symptoms occur in multiple settings and are associated with at least moderate impairment in multiple domains. Severe ADHD is defined when multiple 28 29 symptom areas (hyperactivity, inattention and impulsivity) are all present in multiple 30 settings, and when impairment is severe.

1 Symptoms of ADHD can overlap with those of other related disorders. Therefore,

2 care in differential diagnosis is needed. ADHD may also coexist with other disorders.

- 3 Common coexisting conditions in children include disorders of mood, conduct,
- 4 learning, motor control, language and communication, and anxiety disorders; in
- 5 adults they include personality disorders, bipolar disorder, obsessive-compulsive
- 6 disorder and substance misuse. Where there are coexisting conditions, it is
- 7 important to try to differentiate the level of impairment due to ADHD, as this will
- 8 guide the treatment plan. In addition ADHD is under-recognised in some populations,
- 9 which can mean that a lack of appropriate diagnosis and treatment adversely affects
- 10 people's quality of life.
- 11 The aim of this guideline is to raise awareness of populations at risk and to provide
- 12 clear advice on managing ADHD.
- 13 The guideline covers children under 5 years, children and young people aged 5 to
- 14 17 years, and adults aged 18 years or over who are at risk of ADHD or have a
- 15 diagnosis of ADHD. The guideline covers all primary, secondary and community care
- 16 settings in which NHS-funded care is provided for people with ADHD.

17 More information

To find out what NICE has said on topics related to this guideline, see our web page on mental health and behavioural conditions.

18

19 Update information

20 February 2018

- 21 This guideline is an update of NICE guideline CG72 (published September 2008)
- 22 and will replace it.
- 23 New recommendations have been added on recognition, information and support,
- 24 managing ADHD (including non-pharmacological treatment), medication, follow-up
- and monitoring, adherence, and review of medication and discontinuation.
- 26 These are marked as: [2018]

- 1 NICE proposes to delete some recommendations from the 2008 guideline, because
- 2 either the evidence has been reviewed and the recommendations have been
- 3 updated, or NICE has updated other relevant guidance and has replaced the original
- 4 recommendations. <u>Recommendations that have been deleted or changed</u> sets out
- 5 these recommendations and includes details of replacement recommendations.
- 6 Where there is no replacement recommendation, an explanation for the proposed
- 7 deletion is given.
- 8 Where recommendations are shaded in grey and end **[2008]**, the evidence has not
- 9 been reviewed since the original guideline.
- 10 Where recommendations are shaded in grey and end [2008, amended 2018], the
- 11 evidence has not been reviewed but changes have been made to the
- 12 recommendation wording that change the meaning (for example, because of
- 13 equalities duties or a change in the availability of medicines, or incorporated
- 14 guidance has been updated). These changes are marked with yellow shading, and
- 15 explanations of the reasons for the changes are given in 'Recommendations that
- 16 have been deleted or changed' for information.
- 17 See also the <u>original NICE guideline and supporting documents</u>.

18 **Recommendations that have been deleted or changed**

19 Recommendations to be deleted

Recommendation in 2008 guideline	Comment
 Healthcare professionals should develop a trusting relationship with people with ADHD and their families or carers by: respecting the person and their family's knowledge and experience of ADHD being sensitive to stigma in relation to mental illness. (1.1.2.1) 	Replaced by: Healthcare professionals working with children and young people with ADHD should follow the recommendations on general principles of care in NICE's guideline on antisocial behaviour and conduct disorder in children and young people. This does not mean that all children and young people with ADHD have coexisting antisocial behaviour and conduct disorder but that the same general principles of care apply when working with children and young people. [2018] (1.4.2)
Healthcare professionals should provide people with ADHD and their families	Replaced by:

or carers with relevant, age-appropriate information (including written information) about ADHD at every stage of their care. The information should cover diagnosis and assessment, support and self-help, psychological treatment, and the use and possible side effects of drug treatment. (1.1.2.2)	Use this guideline with the NICE guidelines on service user experience in adult mental health and patient experience in adult NHS services to improve the experience of care for adults with ADHD. The principles also apply to children and young people and their parents or carers. [2018] (1.4.1) Healthcare professionals working with
	children and young people with ADHD should follow the recommendations on general principles of care in NICE's guideline on antisocial behaviour and conduct disorder in children and young people. This does not mean that all children and young people with ADHD have coexisting antisocial behaviour and conduct disorder but that the same general principles of care apply when working with children and young people. [2018] (1.4.2)
	 Following a diagnosis of ADHD, have a structured discussion with people (and their families or carers as appropriate) about how ADHD could affect their life. This could include: the positive impacts of receiving a diagnosis, such as: improving their understanding of symptoms identifying and building on individual strengths improving access to services the negative impacts of receiving a diagnosis, such as stigma and labelling a greater tendency for impulsive behaviour the increased risk of substance misuse and self-medication
	 the possible effect on driving (for example, some ADHD medication may impact on a person's fitness to drive and people with ADHD must declare their diagnosis to the DVLA if it affects their driving) the challenges of managing ADHD when a person has coexisting neurodevelopmental or mental health conditions education and employment issues (for example, impact on career

 choices and rights to reasonable adjustments at school and college, and in the workplace) social relationship issues. This should inform the shared treatment plan. [2018] (1.4.4)
 Improve communication by providing information to people with ADHD (and their families and carers as appropriate) that: takes into account their developmental level, cognitive style, emotional maturity and cognitive capacity, including any learning disabilities, sight or hearing problems, delays in language development or social communication difficulties takes into account any coexisting neurodevelopmental and mental health conditions is tailored to their individual needs and circumstances, including age, gender, educational level and life stage. [2018] (1.4.6)

included in ons: le with nbers or involved in isions; such
nbers or involved in isions; such
ce at intervals ges in
velopmental n only once.
nt for ADHD, d their family ncouraging o give their el:
ms of non- atments (for y of ed with no armacological side effects ates) Ithy lifestyle, d concerns on's decision top treatment y media family d differing ty of ADHD nts) ealth or conditions nt choices therence to actors that xample, it ke medication ences and plan. [2018]
orking with with ADHD adations on NICE's
d find o colling d the colling d correction of the colling d colling d colling d colling d col

 able to assess the young person's understanding of issues related to ADHD and its treatment (including Gillick competence) familiar with parental consent and responsibilities, child protection issues, the Mental Health Act (2007) and the Children Act (1989). (1.1.2.4) Healthcare professionals should work with children and young people with ADHD and their parents or carers to anticipate major life changes (such as puberty, starting or changing schools, the birth of a sibling) and make appropriate arrangements for adequate personal and social support during times of increased need. The need for psychological treatment at these times should be considered. (1.1.2.5) 	guideline on antisocial behaviour and conduct disorder in children and young people. This does not mean that all children and young people with ADHD have coexisting antisocial behaviour and conduct disorder but that the same general principles of care apply when working with children and young people. [2018] (1.4.2) Replaced by: Regularly discuss with people with ADHD, and their family members or carers, how they want to be involved in treatment planning and decisions; such discussions should take place at intervals to take account of any changes in circumstances, including developmental level, and should not happen only once. [2018] (1.5.3)
	Penlaced by:
Adults with ADHD should be given written information about local and national support groups and voluntary organisations. (1.1.2.6)	Replaced by: Tell people receiving a diagnosis of ADHD (and their families or carers as appropriate) about:
	 local and national support groups and voluntary organisations
	 sources of more information, including websites
	 support for education and employment. [2018] (1.4.5)
Healthcare professionals should ask families or carers about the impact of ADHD on themselves and other family members, and discuss any concerns they may have. Healthcare professionals should:	Replaced by: Ask families or carers of people with ADHD how the ADHD affects themselves and other family members, and discuss any concerns they have. [2018] (1.4.7)
 offer family members or carers an assessment of their personal, social and mental health needs encourage participation in self-help and support groups where appropriate 	Encourage family members or carers of people with ADHD to seek an assessment of their personal, social and mental health needs, and to join self-help and support groups if appropriate. [2018] (1.4.8)
 offer general advice to parents and carers about positive parent– and carer–child contact, clear and appropriate rules about babayiour, and the 	Offer advice to parents and carers of children and young people with ADHD about the importance of: • positive parent– and carer–child
rules about behaviour, and the importance of structure in the child or young person's day	 positive parent– and carer–child contact clear and appropriate rules about behaviour
 explain that parent- 	υστιανισμί

training/education programmes	structure in the child or young
do not necessarily imply bad parenting, and that their aim is to	person's day. [2018] (1.4.9)
optimise parenting skills to meet the above-average parenting needs of children and young	Offer advice to families and carers of adults with ADHD about:
people with ADHD. (1.1.2.7)	 how ADHD may affect relationships
	 how ADHD may affect the person's functioning
	• the importance of structure in daily activities. [2018] (1.4.10)
	Explain to parents and carers that any recommendation of parent- training/education does not imply bad parenting, and that the aim is to optimise parenting skills to meet the above- average parenting needs of children and young people with ADHD. [2018] (1.4.11)
A child or young person who is currently treated in primary care with methylphenidate, atomoxetine, dexamfetamine, or any other psychotropic drug for a presumptive diagnosis of ADHD, but has not yet been assessed by a specialist in ADHD in secondary care, should be referred for assessment to a child psychiatrist, paediatrician, or specialist ADHD CAMHS as a matter of clinical priority. (1.2.1.9)	This recommendation has been deleted because the committee agreed that a child or young person should only have diagnosis and treatment confirmed by a specialist in ADHD. This recommendation is at odds with recommendation 1.2.1.8 in the 2008 guideline.
Following a diagnosis of ADHD, healthcare professionals should consider providing all parents or carers of all	This recommendation has been replaced with a larger section on information and support:
children and young people with ADHD	Tell secole secole in a discussion for the
self-instruction manuals, and other materials such as videos, based on positive parenting and behavioural	Tell people receiving a diagnosis of ADHD (and their families or carers as appropriate) about:
techniques. (1.4.1.1)	 local and national support groups and voluntary organisations
	 sources of more information, including websites
	 support for education and employment. [2018] (1.4.5)
	Improve communication by providing information to people with ADHD (and their families and carers as appropriate) that:
	takes into account their

	developmental level, cognitive
	style, emotional maturity and cognitive capacity, including any learning disabilities, sight or
	hearing problems, delays in language development or social communication difficulties
	 takes into account any coexisting neurodevelopmental and mental health conditions
	 is tailored to their individual needs and circumstances, including age, gender, educational level and life stage. [2018](1.4.6)
	Offer advice to parents and carers of children and young people with ADHD about the importance of:
	 positive parent– and carer–child contact
	 clear and appropriate rules about behaviour
	 structure in the child or young person's day. [2018] (1.4.9)
Drug treatment is not recommended for pre-school children with ADHD. (1.5.1.1)	Replaced by: Offer an ADHD-focused group parent- training programme to parents or carers of children under 5 years with ADHD as first-line treatment. See the recommendations 1.5.1 to 1.5.10 in
	NICE's guideline on antisocial behaviour and conduct disorders in children and young people. [2018] (1.5.7)
	NICE's guideline on antisocial behaviour and conduct disorders in children and
Following a diagnosis of ADHD in a child	NICE's guideline on antisocial behaviour and conduct disorders in children and young people. [2018] (1.5.7) If after an ADHD-focused group parent- training programme, ADHD symptoms are still causing severe impairment across more than one domain in a child under 5 years, obtain specialist advice (ideally from a tertiary service). [2018] (1.5.8) Replaced by:
Following a diagnosis of ADHD in a child of pre-school age, healthcare professionals should, with the parents' or carers' consent, contact the child's	NICE's guideline on antisocial behaviour and conduct disorders in children and young people. [2018] (1.5.7) If after an ADHD-focused group parent- training programme, ADHD symptoms are still causing severe impairment across more than one domain in a child under 5 years, obtain specialist advice (ideally from a tertiary service). [2018] (1.5.8)
of pre-school age, healthcare professionals should, with the parents' or carers' consent, contact the child's nursery or pre-school teacher to explain:	NICE's guideline on antisocial behaviour and conduct disorders in children and young people. [2018] (1.5.7) If after an ADHD-focused group parent- training programme, ADHD symptoms are still causing severe impairment across more than one domain in a child under 5 years, obtain specialist advice (ideally from a tertiary service). [2018] (1.5.8) Replaced by: When ADHD is diagnosed, when symptoms change, and when there is transition between schools or from school to college, obtain consent and then
of pre-school age, healthcare professionals should, with the parents' or carers' consent, contact the child's nursery or pre-school teacher to explain: • the diagnosis and severity of	NICE's guideline on antisocial behaviour and conduct disorders in children and young people. [2018] (1.5.7) If after an ADHD-focused group parent- training programme, ADHD symptoms are still causing severe impairment across more than one domain in a child under 5 years, obtain specialist advice (ideally from a tertiary service). [2018] (1.5.8) Replaced by: When ADHD is diagnosed, when symptoms change, and when there is transition between schools or from school to college, obtain consent and then contact the school or college to explain:
of pre-school age, healthcare professionals should, with the parents' or carers' consent, contact the child's nursery or pre-school teacher to explain:	NICE's guideline on antisocial behaviour and conduct disorders in children and young people. [2018] (1.5.7) If after an ADHD-focused group parent- training programme, ADHD symptoms are still causing severe impairment across more than one domain in a child under 5 years, obtain specialist advice (ideally from a tertiary service). [2018] (1.5.8) Replaced by: When ADHD is diagnosed, when symptoms change, and when there is transition between schools or from school to college, obtain consent and then

(1.5.1.2)	life
	 other coexisting conditions (for example, learning disabilities) are distinct from ADHD and may need different adjustments
	 the treatment plan and identified special educational needs, including advice for environmental and learning modifications
	 the value of feedback from schools and colleges to people with ADHD and their healthcare professionals. (1.4.12)
Healthcare professionals should offer parents or carers of pre-school children with ADHD a referral to a parent- training/education programme as the first-line treatment if the parents or carers have not already attended such a programme or the programme has had a limited effect. (1.5.1.3)	Replaced by: Offer an ADHD-focused parent-training programme to parents or carers of children under 5 years with ADHD as first-line treatment. See recommendations 1.5.1 to 1.5.10 in NICE's guideline on <u>antisocial behaviour</u> <u>and conduct disorders in children and</u> young people. (1.5.7)
Group-based parent-training/education programmes, developed for the treatment and management of children with conduct disorders, should be fully accessible to parents or carers of children with ADHD whether or not the child also has a formal diagnosis of conduct disorder. (1.5.1.4)	Replaced by: Offer parents and carers of all children and young people aged 5 years and over with ADHD group-based ADHD-focused support that includes education and information on causes and impacts of ADHD and advice on parenting strategies. This may be as few as 1 or 2 sessions and should include both parents and carers if feasible. (1.5.9)
	If a child or young person aged 5 years or over has ADHD and symptoms of oppositional defiant disorder or conduct disorder, offer parents and carers a parent-training programme in line with recommendations 1.5.1 to 1.5.10 in NICE's guideline on antisocial behaviour and conduct disorders in children and young people as well as group-based ADHD-focused support. [2018] (1.5.11)
Individual-based parent-	Replaced by:
 training/education programmes are recommended in the management of children with ADHD when: a group programme is not 	Consider individual parent- training/education programmes for parents and carers of children and young people with ADHD when:
possible because of low participant numbers	there are particular difficulties for families in attending group

 there are particular difficulties for families in attending group sessions (for example, because of disability, needs related to diversity such as language differences, parental ill-health, problems with transport, or where other factors suggest poor prospects for therapeutic engagement) a family's needs are too complex to be met by group-based parent-training/education programmes. (1.5.1.5) 	 sessions [for example, because of disability, needs related to diversity such as language differences, learning disability (intellectual disability), parental ill-health, problems with transport, or where other factors suggest poor prospects for therapeutic engagement] a family's needs are too complex to be met by group-based parent-training/education programmes. (1.5.13)
When individual-based parent- training/education programmes for pre- school children with ADHD are undertaken, the skills training stages should involve both the parents or carers and the child. (1.5.1.6)	This recommendation has been deleted because the committee highlighted the importance of both parents or carers attending group sessions and considered that both parents or carers attending individual programmes is implicit in the complex needs or difficulties the family have.
This recommendation has been replaced by recommendations 1.5.2 and 1.5.4 in antisocial behaviour and conduct disorders in children and young people (NICE guideline CG158). (1.5.1.7)	Replaced by If a child or young person aged 5 years or over has ADHD and symptoms of oppositional defiant disorder or conduct disorder, offer parents and carers a parent-training programme in line with recommendations 1.5.1 to 1.5.10 in NICE's guideline on antisocial behaviour and conduct disorders in children and young people as well as group-based ADHD-focused support. [2018] (1.5.11)
Consideration should be given to involving both of the parents or all carers of children or young people with ADHD in parent-training/education programmes wherever this is feasible. (1.5.1.8)	Replaced by : Offer parents and carers of all children and young people aged 5 years and over with ADHD, group-based ADHD-focused support that includes education and information on causes and impacts of ADHD and advice on parenting strategies. This may be as few as 1 or 2 sessions and should include both parents and carers if feasible. [2018] (1.5.9)
This recommendation has been replaced by recommendations 1.5.2 and 1.5.4 in antisocial behaviour and conduct disorders in children and young people (NICE guideline CG158). (1.5.1.9)	Replaced by If a child or young person aged 5 years or over has ADHD and symptoms of oppositional defiant disorder or conduct disorder, offer parents and carers a parent-training programme in line with recommendations 1.5.1 to 1.5.10 in NICE's guideline on antisocial behaviour and conduct disorders in children and

	young people as well as group-based ADHD-focused support. [2018] (1.5.11)
 If overall treatment, including parent-training/education programmes, has been effective in managing ADHD symptoms and any associated impairment in pre-school children, before considering discharge from secondary care healthcare professionals should: review the child, with their parents or carers and siblings, for any residual coexisting conditions and develop a treatment plan for these if needed monitor for the recurrence of ADHD symptoms and any associated impairment that may occur after the child starts school. 	This recommendation has been deleted because the committee agreed the emphasis should be on review of the symptoms and treatment not on discharge.
(1.5.1.11) If overall treatment, including parent- training/education programmes, has not been effective in managing ADHD symptoms and any associated impairment in pre-school children, healthcare professionals should consider referral to tertiary services for further care. (1.5.1.12)	Replaced by: If after an ADHD-focused parent-training programme, ADHD symptoms are still causing severe impairment across more than one domain in a child under 5 years, obtain specialist advice (ideally from a tertiary service). [2018] (1.5.8)
Drug treatment is not indicated as the first-line treatment for all school-age children and young people with ADHD. It should be reserved for those with severe symptoms and impairment or for those with moderate levels of impairment who have refused non-drug interventions, or whose symptoms have not responded sufficiently to parent-training/education programmes or group psychological treatment. (1.5.2.1)	Replaced by: Offer medication to children and young people with ADHD aged 5 years and over if their ADHD symptoms are having a persistent significant impact in at least domain of their everyday life after environmental modifications. See the recommendations on medication choice [2018] (1.5.10)
 Following a diagnosis of ADHD in a school-age child or young person healthcare professionals should, with the parents' or carers' consent, contact the child or young person's teacher to explain: the diagnosis and severity of symptoms and impairment the care plan any special educational needs. (1.5.2.2) 	 Replaced by: When ADHD is diagnosed, when symptoms change, and when there is transition between schools or from school to college, obtain consent and then contact the school or college to explain: the validity of a diagnosis of ADHD and how symptoms are likely to affect school or college life other coexisting conditions (for example, learning disabilities) are distinct from ADHD and may need

	different adjustments
	different adjustments
	 the treatment plan and identified special educational needs, including advice for environmental and learning modifications
	 the value of feedback from schools and colleges to people with ADHD and their healthcare professionals. [2018] (1.4.12)
Teachers who have received training about ADHD and its management should provide behavioural interventions in the classroom to help children and young people with ADHD. (1.5.2.3)	This recommendation has been deleted because the guideline is directed at people providing services for the NHS.
If the child or young person with ADHD	Replaced by:
has moderate levels of impairment, the parents or carers should be offered referral to a group parent- training/education programme, either on its own or together with a group treatment programme (CBT and/or social skills training) for the child or young person. (1.5.2.4)	Offer parents and carers of all children and young people aged 5 years and over with ADHD, group-based ADHD-focused support that includes education and information on causes and impacts of ADHD and advice on parenting strategies. This may be as few as 1 or 2 sessions and should include both parents and carers if feasible. [2018] (1.5.9)
	Consider a course of cognitive behavioural therapy (CBT) for young people with ADHD who have benefited from medication but whose symptoms continue to have a significant impact on at least one domain of their everyday life addressing the following areas: • social skills with peers • problem-solving • self-control • active listening skills
	 dealing with and expressing feelings. [2018] (1.5.12)
When using group treatment (CBT and/or social skills training) for the child or young person in conjunction with a parent-training/education programme, particular emphasis should be given to targeting a range of areas, including social skills with peers, problem solving, self-control, listening skills and dealing with and expressing feelings. Active learning strategies should be used, and rewards given for achieving key elements of learning. (1.5.2.5)	Replaced by: Offer parents and carers of all children and young people aged 5 years and over with ADHD, group-based ADHD-focused support that includes education and information on causes and impacts of ADHD and advice on parenting strategies. This may be as few as 1 or 2 sessions and should include both parents and carers if feasible. [2018] (1.5.9) Consider a course of cognitive

For older adolescents with ADHD and moderate impairment, individual psychological interventions (such as CBT or social skills training) may be considered as they may be more effective and acceptable than group parent-training/education programmes or group CBT and/or social skills training. (1.5.2.6)	 behavioural therapy (CBT) for young people with ADHD who have benefited from medication but whose symptoms continue to have a significant impact on at least one domain of their everyday life addressing the following areas: social skills with peers problem-solving self-control active listening skills dealing with and expressing feelings. (1.5.12) Replaced by: Consider a course of cognitive behavioural therapy (CBT) for young people with ADHD who have benefited from medication but whose symptoms continue to have a significant impact on at least one domain of their everyday life, addressing the following areas: social skills with peers problem-solving self-control active listening skills
For children and young people (including older age groups) with ADHD and a learning disability, a parent training/education programme should be offered on either a group or individual basis, whichever is preferred following discussion with the parents or carers and the child or young person. (1.5.2.7)	dealing with and expressing feelings. (1.5.12) Replaced by: Consider individual parent- training/education programmes for parents and carers of children and young people with ADHD when: • there are particular difficulties for families in attending group sessions [for example, because of disability, needs related to diversity such as language differences, learning disability (intellectual disability), parental ill- health, problems with transport, or where other factors suggest poor prospects for therapeutic engagement] • a family's needs are too complex to be met by group-based parent- training/education programmes. [2018] (1.5.13)
young people with ADHD undertake	Replaced by: When ADHD is diagnosed, when

noront training/oducation programmes	aumatama abanga and whan there is
parent-training/education programmes, the professional delivering the sessions should consider contacting the school and providing the child or young person's	symptoms change, and when there is transition between schools or from school to college, obtain consent and then contact the school or college to explain:
teacher with written information on the areas of behavioural management covered in these sessions. This should only be done with parental consent.	 the validity of a diagnosis of ADHD and how symptoms are likely to affect school or college life
(1.5.2.8)	 other coexisting conditions (for example, learning disabilities) are distinct from ADHD and may need different adjustments
	 the treatment plan and identified special educational needs, including advice for environmental and learning modifications
	• the value of feedback from schools and colleges to people with ADHD and their healthcare professionals. [2018] (1.4.12)
Following successful treatment with a parent-training/education programme and before considering discharge from secondary care, the child or young person should be reviewed, with their parents or carers and siblings, for any residual problems such as anxiety, aggression or learning difficulties. Treatment plans should be developed for any coexisting conditions. (1.5.2.9)	This recommendation has been deleted because the committee agreed the emphasis should be on review of the symptoms and treatment not on discharge.
Following treatment with a parent- training/education programme, children and young people with ADHD and persisting significant impairment should be offered drug treatment. (1.5.2.10)	Replaced by: Offer parents and carers of all children and young people aged 5 years and over with ADHD, group-based ADHD-focused support that includes education and information on causes and impacts of ADHD and advice on parenting strategies. This may be as few as 1 or 2 sessions and should include both parents and carers if feasible. [2018] (1.5.9)
In school-age children and young people with severe ADHD, drug treatment should be offered as the first-line treatment. Parents should also be offered a group-based parent-training/education programme. (1.5.2.11)	Replaced by: Offer parents and carers of all children and young people aged 5 years and over with ADHD, group-based ADHD-focused support that includes education and information on causes and impacts of ADHD and advice on parenting strategies. This may be as few as 1 or 2 sessions and should include both parents and carers if feasible. [2018] (1.5.9)

Drug treatment should only be initiated by an appropriately qualified healthcare professional with expertise in ADHD and should be based on a comprehensive assessment and diagnosis. Continued prescribing and monitoring of drug therapy may be performed by general practitioners, under shared care arrangements. (1.5.3.2)	This recommendation has been deleted because the committee agreed that a child or young person should only have diagnosis and treatment confirmed by a specialist in ADHD. This recommendation is at odds with recommendation 1.2.1.8 in the 2008 guideline. After titration and dose stabilisation, prescribing and monitoring should be carried out under shared care arrangements with primary care. [2018] (1.7.24)
If drug treatment is not accepted by the child or young person with severe ADHD, or their parents or carers, healthcare professionals should advise parents or carers and the child or young person about the benefits and superiority of drug treatment in this group. If drug treatment is still not accepted, a group parent training/education programme should be offered. (1.5.3.3)	 Replaced by : Before starting any treatment for ADHD, discuss the following with the person, and their family or carers as appropriate, encouraging children and young people to give their own account of how they feel: the benefits and harms of non-pharmacological and pharmacological treatments (for example, the efficacy of medications compared with no treatment or non-pharmacological treatments, potential side effects and non-response rates) the benefits of a healthy lifestyle, including exercise their preferences and concerns (for example, a person's decision to start, change or stop treatment may be influenced by media coverage, teachers, family members, friends and differing opinion on the validity of ADHD and specific treatments) how other mental health or neurodevelopmental conditions might affect treatment choices the importance of adherence to treatment and any factors that may affect this (for example, it may be difficult to take medication at school or work).

	Reassure people with ADHD, and their families or carers as appropriate, that they can revisit decisions about treatments. [2018] (1.5.6).
If a group parent-training/education programme is effective in children and young people with severe ADHD who have refused drug treatment, healthcare professionals should assess the child or young person for possible coexisting	This recommendation has been deleted because this is covered in the recommendations on the review of treatment and in this new recommendation.
conditions and develop a longer-term care plan. (1.5.3.4)	Regularly discuss with people with ADHD, and their family members or carers, how they want to be involved in treatment planning and decisions; such discussions should take place at intervals to take account of any changes in circumstances, including developmental level, and should not happen only once. [2018] (1.5.3)
If a group parent-training/education	Replaced by:
programme is not effective for a child or young person with severe ADHD, and if drug treatment has not been accepted, discuss the possibility of drug treatment again or other psychological treatment (group CBT and/or social skills training), highlighting the clear benefits and superiority of drug treatment in children or young people with severe ADHD. (1.5.3.5)	Regularly discuss with people with ADHD, and their family members or carers, how they want to be involved in treatment planning and decisions; such discussions should take place at intervals to take account of any changes in circumstances, including developmental level, and should not happen only once. [2018] (1.5.3)
	Before starting any treatment for ADHD, discuss with the person, and their family or carers as appropriate, encouraging children and young people to give their own account of how they feel:
	 the benefits and harms of non- pharmacological and pharmacological treatments (for example, the efficacy of medications compared with no treatment or non-pharmacological treatments, potential side effects and non-response rates)
	 the benefits of a healthy lifestyle, including exercise
	 their preferences and concerns (for example, a person's decision to start, change or stop treatment may be influenced by media

	 coverage, teachers, family members, friends and differing opinion on the validity of ADHD and specific treatments) how other mental health or neurodevelopmental conditions might affect treatment choices the importance of adherence to treatment and any factors that may affect this (for example, it may be difficult to take medication at school or work). Record the person's preferences and concerns in their treatment plan. [2018] (1.5.4) Reassure people with ADHD, and their families or carers as appropriate, that they can revisit decisions about treatments. [2018] (1.5.6). Ensure that children, young people and adults receiving treatment for ADHD have review and follow-up according to the severity of their condition, regardless of whether or not they are taking
 Following a diagnosis of severe ADHD in a school-age child or young person healthcare professionals should, with the parents' or carers' consent, contact the child or young person's teacher to explain: the diagnosis and severity of symptoms and impairment the care plan any special educational needs. (1.5.3.6) 	 medication. [2018] (1.8.3) Replaced by: When ADHD is diagnosed, when symptoms change, and when there is transition between schools or from school to college, obtain consent and then contact, the school or college to explain: the validity of a diagnosis of ADHD and how symptoms are likely to affect school or college life other coexisting conditions (for example, learning disabilities) are distinct from ADHD and may need different adjustments the treatment plan and identified special educational needs, including advice for environmental and learning modifications the value of feedback from schools and colleges to people with ADHD and their healthcare professionals. (1.4.12)
Teachers who have received training about ADHD and its management should	because the guideline is directed at

provide he havie und interventions in the	needle providing convises for the NUIC
provide behavioural interventions in the classroom to help children and young	people providing services for the NHS.
people with ADHD. (1.5.3.7)	
Before starting drug treatment, children	Replaced by:
and young people with ADHD should	Before starting medication, people with
have a full pre-treatment assessment,	ADHD should have a full assessment,
which should include:	which should include:
full mental health and social	• a review to confirm they continue
assessment	to meet the criteria for ADHD and
 full history and physical 	need treatment
examination, including:	 a review of mental health and
 assessment of history of 	social circumstances, including:
exercise syncope, undue	 presence of coexisting mental
breathlessness and other	health and
cardiovascular symptoms	neurodevelopmental
 heart rate and blood pressure 	conditions
(plotted on a centile chart)	 current educational or
 height and weight (plotted on 	employment circumstances
a growth chart)	 risk assessment for
 family history of cardiac 	substance misuse and drug diversion
disease and examination of	
the cardiovascular system	– care needs
 an electrocardiogram (ECG) if 	 a review of physical health, in abudia au
there is past medical or family history of serious cardiac disease,	including:
a history of sudden death in	 a medical history, taking
young family members or	into account conditions that may be
abnormal findings on cardiac	contraindications for
examination	specific medicines
risk assessment for substance	 current medication
misuse and drug diversion (where	 height and weight (measured
the drug is passed on to others	and recorded against the
for non-prescription use). (1.5.4.1)	normal range for age, height
	and sex)
	 baseline pulse and blood
	pressure (measured with an
	appropriately sized cuff and
	compared with the normal
	range for age)
	 an ECG if the treatment may affect the OT interval (for
	affect the QT interval (for example, tricyclics and
	monoamine oxidase
	inhibitors). [2018] (1.7.2)
	Refer for a cardiology opinion before
	starting medication for ADHD if any of the
	following apply:
	 history of congenital heart
	disease or previous cardiac

	surgon
	surgery
	 history of sudden death in a first- degree relative under 40 years, which could suggest a family history of cardiomyopathy or channelopathy
	 shortness of breath on exertion compared with peers
	 fainting on exertion or in response to fright or noise
	 palpitations that are rapid, regular and start and stop suddenly (fleeting occasional bumps are usually ectopic and do not need investigation)
	 chest pain suggesting cardiac origin
	signs of heart failure
	 blood pressure consistently above the 95th centile for age and height. [2018] (1.7.3)
Drug treatment for children and young people with ADHD should always form part of a comprehensive treatment plan	Replaced by this recommendation that applies to all children and young people aged 5 years and over with ADHD:
that includes psychological, behavioural and educational advice and interventions. (1.5.4.2)	Offer parents and carers of all children and young people aged 5 years and over with ADHD, group-based ADHD-focused support that includes education and information on the causes and impacts of ADHD and advice on parenting strategies. This may be as few as 1 or 2 sessions and should include both parents and carers if feasible. [2018] (1.5.9)
	Ensure that people with ADHD have a comprehensive, holistic shared treatment plan that addresses psychological, behavioural and occupational or educational needs. Take into account: • the severity of ADHD symptoms
	and how these affect or may affect a person's life
	their goals
	 the level of impairment and impact on their everyday life
	their resilience and protective factors
	 the relative impact of other neurodevelopmental or mental

	health conditions. [2018] (1.5.2)
Where drug treatment is considered	Replaced by:
appropriate, methylphenidate, atomoxetine and dexamfetamine are recommended, within their licensed indications, as options for the management of ADHD in children and adolescents. (1.5.5.1)	Offer methylphenidate as first-line pharmacological treatment for children aged 5 years and over and young people with ADHD. (1.7.4)
	Consider lisdexamfetamine for children aged 5 years and over and young people whose ADHD symptoms are not responding adequately to methylphenidate. [2018] (1.7.5)
	Consider dexamfetamine for children aged 5 years and over and young people whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile. (1.7.6)
	Offer atomoxetine or guanfacine to children aged 5 years and over and young people if:
	 they cannot tolerate methylphenidate or lisdexamfetamine, or
	 their symptoms have not responded to separate 6-week trials of lisdexamfetamine and methylphenidate, having tried alternative formulations and adequate doses. (1.7.7)
The decision regarding which product to	Replaced by:
 use should be based on the following: the presence of comorbid conditions (for example, tic 	Before starting medication, people with ADHD should have a full assessment, which should include:
disorders, Tourette's syndrome, epilepsy)the different adverse effects of the	 a review to confirm they continue to meet the criteria for ADHD and need treatment
drugs	 a review of mental health and social circumstances, including;
 specific issues regarding compliance identified for the individual child or adolescent, for example problems created by the need to administer a mid-day treatment dose at school 	social circumstances, including: – presence of coexisting mental health and neurodevelopmental conditions
 the potential for drug diversion (where the medication is forwarded on to others for non- 	 current educational or employment circumstances risk assessment for
prescription uses) and/or misusethe preferences of the	substance misuse and drug diversion
	1

child/adolescent and/or his or her	– care needs
parent or guardian. (1.5.5.2)	
, , , , , , , , , , , , , , , , , , ,	 a review of physical health, including:
	 a medical history, taking into account conditions that may be contraindications for specific medicines
	 current medication
	 height and weight (measured and recorded against the normal range for age, height and sex)
	 baseline pulse and blood pressure (measured with an appropriately sized cuff and compared with the normal range for age)
	 an ECG if the treatment may affect the QT interval (for example, tricyclics and monoamine oxidase inhibitors). [2018] (1.7.2)
When a decision has been made to treat	Replaced by:
children or young people with ADHD	Offer methylphenidate as first-line pharmacological treatment for children
with drugs, healthcare professionals should consider:	aged 5 years and over and young people
methylphenidate for ADHD	with ADHD. (1.7.4)
without significant comorbidity	Consider lisdexamfetamine for children
 methylphenidate for ADHD with comorbid conduct disorder 	aged 5 years and over and young people whose ADHD symptoms are not
 methylphenidate or atomoxetine when tics, Tourette's syndrome, 	responding adequately to methylphenidate. [2018] (1.7.5)
anxiety disorder, stimulant misuse	
or risk of stimulant diversion are present	Consider dexamfetamine for children aged 5 years and over and young people
 atomoxetine if methylphenidate 	whose ADHD symptoms are responding
has been tried and has been ineffective at the	to lisdexamfetamine but who cannot tolerate the longer effect profile. (1.7.6)
 maximum tolerated dose, or the child or young person is intolerant to low or moderate doses of methylphenidate. (1.5.5.3) 	 Offer atomoxetine or guanfacine to children aged 5 years and over and young people if: they cannot tolerate methylphenidate or lisdexamfetamine, or their symptoms have not responded to separate 6-week trials of lisdexamfetamine and
	methylphenidate, having tried alternative formulations and

adaguata dagag $(1, 7, 7)$
adequate doses. (1,7,7)

 When prescribing methylphenidate for the treatment of children or young people, modified-release preparations should be considered for the following reasons: convenience improving adherence reducing stigma (because the child or young person does not need to take medication at school) reducing problems schools have in storing and administering controlled drugs their pharmacokinetic profiles. Alternatively, immediate-release preparations may be considered if more flexible dosing regimens are required, or during initial titration to determine correct dosing levels. (1.5.5.4) When starting drug treatment children and young people should be monitored for side effects. In particular, those treated with atomoxetine should be closely observed for agitation, irritability, suicidal thinking and self-harming behaviour, and unusual changes in behaviour, particularly during the initial months of treatment, or after a change in dose. Parents and/or carers should be warned about the potential for suicidal thinking and self-harming behaviour with atomoxetine and asked to report these to their healthcare professionals. Parents or carers should also be warned about the potential for liver damage in rare cases with atomoxetine (usually presenting as abdominal pain, unexplained nausea, malaise, darkening of the urine or jaundice). (1.5.5.5) 	 Replaced by: When prescribing stimulants for ADHD, think about modified-release once-daily preparations for the following reasons: convenience improving adherence reducing stigma (because there is no need to take medication at school or in the workplace) reducing problems of storing and administering controlled drugs at school the risk of stimulant misuse and diversion with immediate-release preparations their pharmacokinetic profiles. Immediate-release preparations may be suitable if more flexible dosing regimens are needed, or during initial titration to determine correct dosing levels. (1.7.25) This recommendation has been deleted because it has been replaced by section <i>1.8 Follow-up and monitoring</i>.
If there is a choice of more than one appropriate drug, the product with the lowest cost (taking into account the cost per dose and number of daily doses) should be prescribed. (1.5.5.6) Antipsychotics are not recommended for the treatment of ADHD in children and young people. (1.5.5.7) If there has been a poor response following parent-training/education	This recommendation has been deleted because this is implicit in the cost effectiveness decision making. This recommendation has been deleted because they are not recommended. Replaced by :

Attention deficit hyperactivity disorder: NICE guideline short version DRAFT (September 2017) 69 of 93

 programmes and/or psychological treatment and treatment with methylphenidate and atomoxetine in a child or young person with ADHD, there should be a further review of: the diagnosis any coexisting conditions response to drug treatment, occurrence of side effects and treatment adherence uptake and use of psychological interventions for the child or young person and their parents or carers effects of stigma on treatment acceptability concerns related to school and/or family motivation of the child or young person and the parents or carers the child or young person's diet. (1.5.6.1) 	Obtain a second opinion or refer to tertiary services if ADHD symptoms in a child aged 5 years or over, a young person or adult are unresponsive to one or more stimulants and one non- stimulant. [2018] (1.7.12)
treatment, a dose higher than that licensed for methylphenidate or atomoxetine should be considered following consultation with a tertiary or regional centre. This may exceed 'British national formulary' (BNF) recommendations: methylphenidate can be increased to 0.7 mg/kg per dose up to three times a day or a total daily dose of 2.1 mg/kg/day (up to a total maximum dose of 90 mg/day for immediate release; or an equivalent dose of modified-release methylphenidate)[5]; atomoxetine may be increased to 1.8 mg/kg/day (up to a total maximum dose of 120 mg/day). The prescriber should closely monitor the child or young person for side effects. (1.5.6.2)	by the initiation and titration section.
Dexamfetamine should be considered in children and young people whose ADHD is unresponsive to a maximum tolerated dose of methylphenidate or atomoxetine. (1.5.6.3)	Replaced by: Consider dexamfetamine for children aged 5 years and over and young people whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile. (1.7.6)
In children and young people whose ADHD is unresponsive to methylphenidate, atomoxetine and dexamfetamine, further treatment should	Replaced by: Obtain a second opinion or refer to tertiary services if ADHD symptoms in a

only follow after referral to tertiary services. Further treatment may include the use of medication unlicensed for the treatment of ADHD (such as bupropion, clonidine,	child aged 5 years or over, a young person or adult are unresponsive to one or more stimulants and one non- stimulant. (1.7.12)
modafinil and imipramine) or combination treatments (including psychological treatments for the parent or carer and the child or young person). The use of medication unlicensed for ADHD should only be considered in the context of tertiary services. (1.5.6.4)	Do not offer any medication for ADHD other than in recommendations 1.7.4 to 1.7.11 outside a specialist (tertiary) ADHD service (for example, guanfacine for adults, clonidine for children with ADHD and sleep disturbance, rages or tics). (1.7.13)
A cardiovascular examination and ECG should be carried out before starting treatment with clonidine in children or young people with ADHD. (1.5.6.5)	Replaced by: Before starting medication, people with ADHD should have a full assessment, which should include:
	 a review to confirm they continue to meet the criteria for ADHD and need treatment
	 a review of mental health and social circumstances, including:
	 presence of coexisting mental health and neurodevelopmental conditions
	 current educational or employment circumstances
	 risk assessment for substance misuse and drug diversion
	 care needs
	 a review of physical health, including:
	 a medical history, taking into account conditions that may be contraindications for specific medicines
	 current medication
	 height and weight (measured and recorded against the normal range for age, height and sex)
	 baseline pulse and blood pressure (measured with an appropriately sized cuff and compared with the normal range for age)
	 an ECG if the treatment may affect the QT interval (for

	example, tricyclics and
	monoamine oxidase inhibitors). (1.7.2)
	Refer for a cardiology opinion before starting medication for ADHD if any of the following apply:
	 history of congenital heart disease or previous cardiac surgery
	 history of sudden death in a first- degree relative under 40 years, which could suggest a family history of cardiomyopathy or channelopathy
	 shortness of breath on exertion compared with peers
	 fainting on exertion or in response to fright or noise
	 palpitations that are rapid, regular and start and stop suddenly (fleeting occasional bumps are usually ectopic and do not need investigation)
	 chest pain suggesting cardiac origin
	signs of heart failure
	 blood pressure consistently above the 95th centile for age and height. (1.7.3)
For adults with ADHD, drug treatment[7]	Replaced by:
should be the first-line treatment unless the person would prefer a psychological approach. (1.7.11)	Offer medication to adults with ADHD if their ADHD symptoms are having a significant impact on at least one domain of their everyday life after environmental modifications. See the recommendations on medication choice. (1.5.14)
Drug treatment for adults with ADHD should be started only under the guidance of a psychiatrist, nurse prescriber specialising in ADHD, or other clinical prescriber with training in the diagnosis and management of ADHD.	This recommendation has been deleted because the committee agreed that a child or young person should only have diagnosis and treatment confirmed by a specialist in ADHD as is stated in the recommendations on diagnosis in the guideline.
Before starting drug treatment for adults with ADHD a full assessment should be completed, which should include:	Before starting medication, people with ADHD should have a full assessment, which should include:
 full mental health and social assessment 	 a review to confirm they continue to meet the criteria for ADHD and

- full history and physical examination, including:
 - assessment of history of exercise syncope, undue breathlessness and other cardiovascular symptoms
 - heart rate and blood pressure (plotted on a centile chart)
 - weight
 - family history of cardiac disease and examination of the cardiovascular system
- an ECG if there is past medical or family history of serious cardiac disease, a history of
- sudden death in young family members or abnormal findings on cardiac examination
- risk assessment for substance misuse and drug diversion. (1.7.1.3)

need treatment

- a review of mental health and social circumstances, including:
 - presence of coexisting mental health and neurodevelopmental conditions
 - current educational or employment circumstances
 - risk assessment for substance misuse and drug diversion
 - care needs
- a review of physical health, including:
 - a medical history, taking into account conditions that may be contraindications for specific medicines
 - current medication
 - height and weight (measured and recorded against the normal range for age, height and sex)
 - baseline pulse and blood pressure (measured with an appropriately sized cuff and compared with the normal range for age)
 - an ECG if the treatment may affect the QT interval (for example, tricyclics and monoamine oxidase inhibitors). (1.7.2)

Refer for a cardiology opinion before starting medication for ADHD if any of the following apply:

- history of congenital heart disease or previous cardiac surgery
- history of sudden death in a firstdegree relative under 40 years, which could suggest a family history of cardiomyopathy or channelopathy
- shortness of breath on exertion compared with peers
- fainting on exertion or in response

 bits of the transmission of the t		
and start and stop suddenly (fleeting occasional bumps are usually ectopic and do not need investigation)Drug treatment for adults with ADHD should always form part of a comprehensive treatment programme that addresses psychological, behavioural and educational or occupational needs. (1.7.1.4)Replaced by: Ensure that people with ADHD have a comprehensive treatment programme that addresses psychological, behavioural and educational or occupational needs. (1.7.1.4)Replaced by: Ensure that people with ADHD have a comprehensive treatment programme that addresses psychological, behavioural and educational or occupational needs. (1.7.1.4)Replaced by: Ensure that people with ADHD have a comprehensive treatment programme that addresses psychological, behavioural and educational or occupational needs. (1.7.1.4)Replaced by: Ensure that people with ADHD have a comprehensive treatment programme that addresses psychological, behavioural and educational or occupational needs. (1.7.1.4)Replaced by: Tollowing a decision to start drug treatment in adults with ADHD, methylphenidate (his should usually be theol their resilience and protective factorsFollowing a decision to start drug treatment in adults unresponsive or intolerant to an adequate trial of methylphenidate (his should usually be about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6)Replaced by: Offer atomoxetine to adults if: • they cannot tolerate lisdexamfetamine or methylphenidate, or • their symptoms have not responded to separate 6-week trials of lisdexamfetamine and		v
originoriginsigns of heart failureblood pressure consistently above the 95th centile for age and height. (1.7.3)Drug treatment for adults with ADHD should always form part of a comprehensive treatment programme that addresses psychological, behavioural and educational or occupational needs. (1.7.1.4)Replaced by:Ensure that people with ADHD have a comprehensive, holistic shared treatment plan that addresses psychological, behavioural and occupational or occupational needs. (1.7.1.4)Replaced by:Ensure that people with ADHD have a comprehensive, holistic shared treatment on their addresses psychological, behavioural and occupational or educational needs. Take into account: • the severity of ADHD symptoms and how these affect or may affect a person's life• their goals• the relative impact of other neurodevelopmental or mental heatth conditions. [2018] (1.5.2)Following a decision to start drug treatment in adults with ADHD, methylphenidate should normally be tried first. (1.7.1.5)Atomoxetine or dexamfetamine should be considered in adults unresponsive or intolerant to an adequate trial of methylphenidate (this should usually be about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6)(1.7.1.6)Offer atomoxetine to adults if: • they cannot tolerate lisdexamfetamine or methylphenidate, or • their symptoms have not responded to separate 6-week trials of lisdexamfetamine and		and start and stop suddenly (fleeting occasional bumps are usually ectopic and do not need
 blood pressure consistently above the 95th centile for age and height. (1.7.3) Drug treatment for adults with ADHD should always form part of a comprehensive treatment programme that addresses psychological, behavioural and educational or occupational needs. (1.7.1.4) Replaced by: Ensure that people with ADHD have a comprehensive, holistic shared treatment plan that addresses psychological, behavioural and educational or occupational needs. (1.7.1.4) the severity of ADHD symptoms and how these affect or may affect a person's life the level of impairment and impact on their everyday life their resilience and protective factors the relative impact of other neurodevelopmental or mental health conditions. [2018] (1.5.2) Following a decision to start drug treatment in adults with ADHD, methylphenidate should normally be tried first. (1.7.1.5) Atomoxetine or dexamfetamine should be considered in adults unresponsive or intolerant to an adequate trial of methylphenidate (this should usually be about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6) Offer atomoxetine to adults if: • they cannot tolerate lisdexamfetamine or methylphenidate, or their symptoms have not responded to separate 6-week trials of lisdexamfetamine and 		
the 95th centile for age and height. (1.7.3)Drug treatment for adults with ADHD should always form part of a comprehensive treatment programme that addresses psychological, behavioural and educational or occupational needs. (1.7.1.4)Replaced by: Ensure that people with ADHD have a comprehensive, holistic shared treatment plan that addresses psychological, behavioural and occupational or educational needs. Take into account:• the severity of ADHD symptoms and how these affect or may affect a person's life• the severity of ADHD symptoms and how these affect or may affect a person's life• their goals• their resilience and protective factors• the relative impact of other neurodevelopmental or mental health conditions. [2018] (1.5.2)Following a decision to start drug treatment in adults with ADHD, methylphenidate should normally be tried first (1.7.1.5)Atomoxetine or dexamfetamine should be considered in adults unresponsive or intolerant to an adequate trial of methylphenidate (this should usually be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6)(1.7.1.6)Offer atomoxetine to adults if: • they cannot tolerate lisdexamfetamine or methylphenidate, or • their symptoms have not responded to separate 6-week trials of lisdexamfetamine and		 signs of heart failure
 should always form part of a comprehensive treatment programme that addresses psychological, behavioural and educational or occupational needs. (1.7.1.4) Ensure that people with ADHD have a comprehensive, holistic shared treatment plan that addresses psychological, behavioural and occupational or educational needs. Take into account: the severity of ADHD symptoms and how these affect or may affect a person's life the severity of ADHD symptoms and how these affect or may affect a person's life the ig goals the level of impairment and impact on their everyday life their resilience and protective factors the relative impact of other neurodevelopmental or mental health conditions. [2018] (1.5.2) Following a decision to start drug treatment in adults with ADHD, methylphenidate should normally be tried first. (1.7.1.5) Atomoxetine or dexamfetamine should be considered in adults unresponsive or intolerant to an adequate trial of methylphenidate (this should usually be about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6) Keplaced by: Consider dexamfetamine for adults if: they cannot tolerate lisdexamfetamine or methylphenidate, or they cannot tolerate lisdexamfetamine or methylphenidate, or 		the 95th centile for age and
 comprehensive treatment programme that addresses psychological, behavioural and educational or occupational needs. (1.7.1.4) comprehensive, holistic shared treatment plan that addresses psychological, behavioural and occupational or occupational needs. (1.7.1.4) comprehensive, holistic shared treatment plan that addresses psychological, behavioural and occupational or occupational needs. (1.7.1.4) comprehensive, holistic shared treatment plan that addresses psychological, behavioural and occupational or occupational needs. (1.7.1.4) comprehensive, holistic shared treatment plan that addresses psychological, behavioural and occupational or occupational or educational needs. Take into account: the severity of ADHD symptoms and how these affect or may affect a person's life their goals the level of impairment and impact on their everyday life their resilience and protective factors the relative impact of other neurodevelopmental or mental health conditions. [2018] (1.5.2) Following a decision to start drug treatment in adults with ADHD, methylphenidate should normally be tried first. (1.7.1.5) Replaced by: Offer lisdexamfetamine as first-line pharmacological treatment for adults with ADHD. (1.7.8) Replaced by: Consider dexamfetamine for adults with ADHD. (1.7.8) Momoxetine or dexamfetamine should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6) Offer atomoxetine to adults if: they cannot tolerate lisdexamfetamine or methylphenidate, or their symptoms have not responded to separate 6-week trials of lisdexamfetamine and 		Replaced by:
 and how these affect or may affect a person's life their goals the level of impairment and impact on their everyday life their resilience and protective factors the relative impact of other neurodevelopmental or mental health conditions. [2018] (1.5.2) Following a decision to start drug treatment in adults with ADHD, methylphenidate should normally be tried first. (1.7.1.5) Replaced by: Offer lisdexamfetamine as first-line pharmacological treatment for adults with ADHD. (1.7.8) Atomoxetine or dexamfetamine should be considered in adults unresponsive or intolerant to an adequate trial of methylphenidate (this should usually be about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6) Offer atomoxetine to adults if: they cannot tolerate lisdexamfetamine, or they cannot tolerate lisdexamfetamine, or they cannot tolerate lisdexamfetamine, or 	comprehensive treatment programme that addresses psychological, behavioural and educational or	comprehensive, holistic shared treatment plan that addresses psychological, behavioural and occupational or
 the level of impairment and impact on their everyday life their resilience and protective factors the relative impact of other neurodevelopmental or mental health conditions. [2018] (1.5.2) Following a decision to start drug treatment in adults with ADHD, methylphenidate should normally be tried first. (1.7.1.5) Atomoxetine or dexamfetamine should be considered in adults unresponsive or intolerant to an adequate trial of methylphenidate (this should usually be about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6) Replaced by: Consider dexamfetamine for adults whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile. (1.7.10) Offer atomoxetine to adults if: • they cannot tolerate lisdexamfetamine or methylphenidate, or • their symptoms have not responded to separate 6-week trials of lisdexamfetamine and 		and how these affect or may
 impact on their everyday life their resilience and protective factors the relative impact of other neurodevelopmental or mental health conditions. [2018] (1.5.2) Following a decision to start drug treatment in adults with ADHD, methylphenidate should normally be tried first. (1.7.1.5) Atomoxetine or dexamfetamine should be considered in adults unresponsive or intolerant to an adequate trial of methylphenidate (this should usually be about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6) Replaced by: Consider dexamfetamine for adults whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile. (1.7.10) Offer atomoxetine to adults if: • they cannot tolerate lisdexamfetamine or methylphenidate, or • their symptoms have not responded to separate 6-week trials of lisdexamfetamine and 		their goals
factorsfactors• the relative impact of other neurodevelopmental or mental health conditions. [2018] (1.5.2)Following a decision to start drug treatment in adults with ADHD, methylphenidate should normally be tried first. (1.7.1.5)Replaced by: Offer lisdexamfetamine as first-line pharmacological treatment for adults with ADHD. (1.7.8)Atomoxetine or dexamfetamine should be considered in adults unresponsive or intolerant to an adequate trial of methylphenidate (this should usually be about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6)Replaced by: Consider dexamfetamine for adults whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile. (1.7.10)Offer atomoxetine to adults if: • they cannot tolerate lisdexamfetamine or methylphenidate, or • their symptoms have not responded to separate 6-week trials of lisdexamfetamine and		•
neurodevelopmental or mental health conditions. [2018] (1.5.2)Following a decision to start drug treatment in adults with ADHD, methylphenidate should normally be tried first. (1.7.1.5)Replaced by: Offer lisdexamfetamine as first-line pharmacological treatment for adults with ADHD. (1.7.8)Atomoxetine or dexamfetamine should be considered in adults unresponsive or intolerant to an adequate trial of methylphenidate (this should usually be about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6)Replaced by: Consider dexamfetamine for adults whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile. (1.7.10)Offer atomoxetine to adults if: • they cannot tolerate lisdexamfetamine or methylphenidate, or • their symptoms have not responded to separate 6-week trials of lisdexamfetamine and		
 treatment in adults with ADHD, methylphenidate should normally be tried first. (1.7.1.5) Atomoxetine or dexamfetamine should be considered in adults unresponsive or intolerant to an adequate trial of methylphenidate (this should usually be about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6) Ciffer lisdexamfetamine as first-line pharmacological treatment for adults with ADHD. (1.7.8) Replaced by: Consider dexamfetamine for adults whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile. (1.7.10) Offer atomoxetine to adults if: • they cannot tolerate lisdexamfetamine or methylphenidate, or • their symptoms have not responded to separate 6-week trials of lisdexamfetamine and 		neurodevelopmental or mental
methylphenidate should normally be tried first. (1.7.1.5)Consider dename to mot methylphenidate (1.7.8)Atomoxetine or dexamfetamine should be considered in adults unresponsive or intolerant to an adequate trial of methylphenidate (this should usually be about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6)Replaced by: Consider dexamfetamine for adults whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile. (1.7.10)Offer atomoxetine to adults if: Isdexamfetamine or methylphenidate, or their symptoms have not responded to separate 6-week trials of lisdexamfetamine and		Replaced by:
be considered in adults unresponsive or intolerant to an adequate trial of methylphenidate (this should usually be about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6) Consider dexamfetamine for adults whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile. (1.7.10) Offer atomoxetine to adults if: • they cannot tolerate lisdexamfetamine or methylphenidate, or • their symptoms have not responded to separate 6-week trials of lisdexamfetamine and	methylphenidate should normally be tried	pharmacological treatment for adults with
intolerant to an adequate trial of methylphenidate (this should usually be about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6)		Replaced by:
 methylphenidate (this should usually be about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6) to lisdexamfetamine but who cannot tolerate the longer effect profile. (1.7.10) Offer atomoxetine to adults if: they cannot tolerate lisdexamfetamine or methylphenidate, or their symptoms have not responded to separate 6-week trials of lisdexamfetamine and 		
 about 6 weeks). Caution should be exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6) Offer atomoxetine to adults if: they cannot tolerate lisdexamfetamine or methylphenidate, or their symptoms have not responded to separate 6-week trials of lisdexamfetamine and 		
 exercised when prescribing dexamfetamine to those likely to be at risk of stimulant misuse or diversion. (1.7.1.6) Offer atomoxetine to adults if: they cannot tolerate lisdexamfetamine or methylphenidate, or their symptoms have not responded to separate 6-week trials of lisdexamfetamine and 		
 risk of stimulant misuse or diversion. (1.7.1.6) they cannot tolerate lisdexamfetamine or methylphenidate, or their symptoms have not responded to separate 6-week trials of lisdexamfetamine and 		(
 (1.7.1.6) lisdexamfetamine or methylphenidate, or their symptoms have not responded to separate 6-week trials of lisdexamfetamine and 		
 methylphenidate, or their symptoms have not responded to separate 6-week trials of lisdexamfetamine and 		•
their symptoms have not responded to separate 6-week trials of lisdexamfetamine and	(1.7.1.0)	
responded to separate 6-week trials of lisdexamfetamine and		
		responded to separate 6-week
methylphenidate, having		
considered alternative formulations		
and doses. (1.7.11)		
When starting drug treatment, adults This recommendation has been deleted	When starting drug treatment, adults	

Attention deficit hyperactivity disorder: NICE guideline short version DRAFT (September 2017) 74 of 93

should be monitored for side effects. In particular, people treated with atomoxetine should be observed for agitation, irritability, suicidal thinking and self-harming behaviour, and unusual changes in behaviour, particularly during the initial months of treatment, or after a change in dose. They should also be warned of potential liver damage in rare cases (usually presenting as abdominal pain, unexplained nausea, malaise, darkening of the urine or jaundice). Younger adults aged 30 years or younger should also be warned of the potential of atomoxetine to increase agitation, anxiety, suicidal thinking and self-harming behaviour in some people, especially during the first few weeks of treatment. (1.7.1.7)	because it has been replaced by section 1.8 Follow-up and monitoring.
For adults with ADHD stabilised on medication but with persisting functional impairment associated with the disorder, or where there has been no response to drug treatment, a course of either group or individual CBT to address the person's functional impairment should be considered. Group therapy is recommended as the first-line psychological treatment because it is the most cost effective. (1.7.1.8)	Replaced by: Consider non-pharmacological treatment in combination with medication for adults with ADHD who have benefited from medication but whose symptoms continue to have a significant impact on at least one domain of their everyday life. (1.5.16)
 For adults with ADHD, CBT may be considered when: the person has made an informed choice not to have drug treatment drug treatment has proved to be only partially effective or ineffective or the person is intolerant to it people have difficulty accepting the diagnosis of ADHD and accepting and adhering to drug treatment symptoms are remitting and psychological treatment is considered sufficient to target residual (mild to moderate) functional impairment. (1.7.1.9) 	 Replaced by: Consider non-pharmacological treatment for adults with ADHD who have: made an informed choice not to have medication difficulty adhering to medication found medication to be ineffective or cannot tolerate it. (1.5.15)
Where there may be concern about the potential for drug misuse and diversion (for example, in prison services), atomoxetine may be considered as the first-line drug treatment for ADHD in	Replaced by: Do not offer immediate-release stimulants or modified-release stimulants that can be easily injected or insufflated if there is a risk of stimulant misuse or

adults. (1.7.1.10)	diversion. [2018] (1.7.15)
	Be cautious about prescribing stimulants for ADHD if there is a risk of stimulant diversion for cognitive enhancement or appetite suppression. [2018] (1.7.16)
Drug treatment for adults with ADHD who also misuse substances should only be prescribed by an appropriately qualified healthcare professional with expertise in managing both ADHD and substance misuse. For adults with ADHD and drug or alcohol addiction disorders there should be close liaison between the professional treating the person's ADHD and an addiction specialist. (1.7.1.11)	This recommendation has been deleted because the committee considered that this described most professionals with expertise in ADHD. A multidisciplinary approach includes this close liaison.
Antipsychotics are not recommended for the treatment of ADHD in adults. (1.7.1.12)	This recommendation has been deleted because they aren't recommended.
Prescribers should be familiar with the pharmacokinetic profiles of all the modified-release and immediate-release preparations available for ADHD to ensure that treatment is tailored effectively to the individual needs of the child, young person or adult. (1.8.1.1)	Replaced by: Healthcare professionals initiating pharmacological treatment should be familiar with the pharmacokinetic profiles of all the modified-release and immediate-release preparations available for ADHD to ensure that treatment is tailored effectively to the individual needs of the child, young person or adult. Different preparations may vary in bioavailability or pharmacokinetic profiles and care needs to be taken to avoid reduced effect or excessive side effects. (1.7.19)
Prescribers should be familiar with the requirements of controlled drug legislation governing the prescription and supply of stimulants. (1.8.1.2)	Replaced by: Prescribers should be familiar with the requirements of controlled drug legislation governing the prescription and supply of stimulants. See NICE's guideline on <u>controlled drugs.</u> (1.7.20)
During the titration phase, doses should be gradually increased until there is no further clinical improvement in ADHD (that is, symptom reduction, behaviour change, improvements in education and/or relationships) and side effects are tolerable. (1.8.1.3)	Replaced by: Titrate the dose against symptoms and side effects in line with the BNF until dose optimisation is achieved, that is, reduced symptoms, positive behaviour change, improvements in education, employment and relationships, with tolerable side effects. (1.7.23)
Following titration and dose stabilisation, prescribing and monitoring should be carried out under locally agreed shared care arrangements with primary care. (1.8.1.4)	Replaced by: After titration and dose stabilisation, prescribing and monitoring should be carried out under shared care

	arrangements with primary care. (1.7.24)
Side effects resulting from drug treatment for ADHD should be routinely monitored and documented in the person's notes. (1.8.1.5)	Replaced by: Monitor side effects resulting from medication for ADHD and document in the person's notes. (1.8.1)
If side effects become troublesome in people receiving drug treatment for ADHD, a reduction in dose should be considered. (1.8.1.6)	Replaced by: Titrate the dose against symptoms and side effects in line with the BNF until dose optimisation is achieved, that is, reduced symptoms, positive behaviour change, improvements in education, employment and relationships, with tolerable side effects. [2018] (1.7.23)
Healthcare professionals should be aware that dose titration should be slower if tics or seizures are present in people with ADHD. (1.8.1.7)	 Replaced by: Ensure that dose titration is slower and monitoring more frequent if any of the following are present in people with ADHD: neurodevelopmental disorders [for example, autism spectrum disorder, tic disorders, learning disability (intellectual disability)] mental health conditions [for example, anxiety disorders (including obsessive–compulsive disorder), schizophrenia or bipolar disorder, depression, personality disorder, eating disorder, post-traumatic stress disorder, substance misuse] physical health conditions (for example, epilepsy or acquired brain injury). (1.7.21)
During the titration phase, symptoms and side effects should be recorded at each dose change on standard scales (for example, Conners' 10-item scale) by parents and teachers, and progress reviewed regularly (for example, by weekly telephone contact and at each dose change) with a specialist clinician. (1.8.2.1) If using methylphenidate in children and	Replaced by: During the titration phase, symptoms and side effects should be recorded at baseline and at each dose change on standard scales (for example, Conners' 10-item scale) by parents and teachers and progress reviewed regularly (for example, by weekly telephone contact) with a specialist. (1.7.22) Replaced by:
 using methylphenidate in children and young people with ADHD aged 6 years and older: initial treatment should begin with low doses of immediate-release or modified-release preparations consistent with starting doses in the BNF 	Titrate the dose against symptoms and side effects in line with the BNF until dose optimisation is achieved, that is, reduced symptoms, positive behaviour change, improvements in education, employment and relationships, with tolerable side effects. [2018] (1.7.23)

 the dose should be titrated against symptoms and side effects over 4–6 weeks until dose optimisation is achieved 	
 modified-release preparations should be given as a single dose in the morning immediate-release preparations should be given in two or three divided doses. (1.8.2.2) 	
 If using atomoxetine in children and young people with ADHD aged 6 years and older: for those weighing up to 70 kg, the initial total daily dose should be approximately 0.5 mg/kg; the dose should be increased after 7 days to approximately 1.2 mg/kg/day 	Replaced by: Titrate the dose against symptoms and side effects in line with the BNF until dose optimisation is achieved, that is, reduced symptoms, positive behaviour change, improvements in education, employment and relationships, with tolerable side effects. [2018] (1.7.23)
 for those weighing more than 70 kg, the initial total daily dose should be 40 mg; the dose should be increased after 7 days up to a maintenance dose of 80 mg/day a single daily dose can be given; two divided doses may be prescribed to minimise side effects. (1.8.2.3) 	
 If using dexamfetamine in children and young people with ADHD: initial treatment should begin with low doses consistent with starting doses in the BNF the dose should be titrated against symptoms and side effects over 4–6 weeks treatment should be given in 	Replaced by: Titrate the dose against symptoms and side effects in line with the BNF until dose optimisation is achieved, that is, reduced symptoms, positive behaviour change, improvements in education, employment and relationships, with tolerable side effects. [2018] (1.7.23)
 divided doses increasing to a maximum of 20 mg/day for children aged 6–18 years, doses up to 40 mg/day may occasionally be required. (1.8.2.4) 	Poplaced by:
In order to optimise drug treatment, the initial dose should be titrated against symptoms and side effects over 4–6 weeks. (1.8.3.1)	Replaced by: Titrate the dose against symptoms and side effects in line with the BNF until dose optimisation is achieved, that is, reduced symptoms, positive behaviour change, improvements in education, employment and relationships, with tolerable side effects. [2018] (1.7.23)
During the titration phase, symptoms and	Replaced by:

side effects should be recorded at each	
dose change by the prescriber after discussion with the person with ADHD and, wherever possible, a carer (for example, a spouse, parent or close friend). Progress should be reviewed (for example, by weekly telephone contact and at each dose change) with a specialist clinician. (1.8.3.2)	During the titration phase, symptoms and side effects should be recorded at baseline and at each dose change on standard scales (for example, Conners' 10-item scale) by parents and teachers and progress reviewed regularly (for example, by weekly telephone contact) with a specialist. [2018] (1.7.22)
If using methylphenidate in adults with ADHD:	Replaced by:
 initial treatment should begin with low doses (5 mg three times daily for immediate-release preparations; the equivalent dose for modified-release preparations) the dose should be titrated against symptoms and side effects over 4–6 weeks 	Titrate the dose against symptoms and side effects in line with the BNF until dose optimisation is achieved, that is, reduced symptoms, positive behaviour change, improvements in education, employment and relationships, with tolerable side effects. [2018] (1.7.23)
 the dose should be increased according to response up to a maximum of 100 mg/day 	
 modified-release preparations should usually be given once daily and no more than twice daily 	
 modified-release preparations may be preferred to increase adherence and in circumstances where there are concerns about substance misuse or diversion 	
 immediate-release preparations should be given up to four times daily. (1.8.3.3) 	
If using atomoxetine in adults with ADHD:	Replaced by:
 for people with ADHD weighing up to 70 kg, the initial total daily dose should be approximately 0.5 mg/kg; the dose should be increased after 7 days to approximately 1.2 mg/kg/day 	Titrate the dose against symptoms and side effects in line with the BNF until dose optimisation is achieved, that is, reduced symptoms, positive behaviour change, improvements in education, employment and relationships, with
 for people with ADHD weighing more than 70 kg, the initial total daily dose should be 40 mg; the dose should be increased after 7 days up to a maintenance dose of 100 mg/day 	tolerable side effects. [2018] (1.7.23)
 the usual maintenance dose is either 80 or 100 mg, which may be taken in divided doses 	
a trial of 6 weeks on a maintenance dose should be	

allowed to evaluate the full effectiveness of atomoxetine. (1.8.3.4)	
 If using dexamfetamine in adults with ADHD: initial treatment should begin with low doses (5 mg twice daily) the dose should be titrated against symptoms and side effects over 4–6 weeks treatment should be given in divided doses the dose should be increased according to response up to a maximum of 60 mg/day the dose should usually be given between two and four times daily. (1.8.3.5) 	Replaced by: Titrate the dose against symptoms and side effects in line with the BNF until dose optimisation is achieved, that is, reduced symptoms, positive behaviour change, improvements in education, employment and relationships, with tolerable side effects. [2018] (1.7.23)
Healthcare professionals should consider using standard symptom and side effect rating scales throughout the course of treatment as an adjunct to clinical assessment for people with ADHD. (1.8.4.1)	Replaced by: Consider using standard symptom and side effect rating scales for clinical assessment and throughout the course of treatment for people with ADHD. (1.8.2)
 In people taking methylphenidate, atomoxetine, or dexamfetamine: height should be measured every 6 months in children and young people weight should be measured 3 and 6 months after drug treatment has started and every 6 months thereafter in children, young people and adults height and weight in children and young people should be plotted on a growth chart and reviewed by the healthcare professional responsible for treatment. (1.8.4.2) 	 Replaced by: For people taking medication for ADHD: measure height every 6 months in children and young people measure weight 3 and 6 months after starting treatment and every 6 months thereafter, or more often if concerns arise plot height and weight of children and young people on a growth chart and ensure review by the healthcare professional responsible for treatment. (1.8.4)
If there is evidence of weight loss associated with drug treatment in adults with ADHD, healthcare professionals should consider monitoring body mass index and changing the drug if weight loss persists. (1.8.4.3)	Replaced by: Consider monitoring body mass index of adults with ADHD if there has been weight change as a result of their treatment, and changing the medication if weight change persists. (1.8.5)
Strategies to reduce weight loss in people with ADHD, or manage decreased weight gain in children, include:	Replaced by: If weight loss is a clinical concern consider the following strategies: • taking medication either with or

 taking medication either with or after food, rather than before meals taking additional meals or snacks early in the morning or late in the evening when the stimulant effects of the drug have worn off obtaining dietary advice consuming high-calorie foods of good nutritional value. If growth is significantly affected by drug treatment (that is, the child or young person has not met the height expected for their age), the option of a planned break in treatment over school holidays should be considered to allow 'catch-up' growth to occur. (1.8.4.5) 	 after food, rather than before meals taking additional meals or snacks early in the morning or late in the evening when stimulant effects have worn off obtaining dietary advice consuming high-calorie foods of good nutritional value a planned break in treatment. (1.8.6) Replaced by: If a child or young person's height or weight over time is significantly affected by medication (that is, they have not met the height expected for their age), consider a planned break in treatment over school holidays to allow 'catch-up' growth. (1.8.7)
In people with ADHD, heart rate and	Replaced by:
blood pressure should be monitored and recorded on a centile chart before and after each dose change and routinely every 3 months. (1.8.4.6)	Monitor heart rate and blood pressure and compare with the normal range for age before and after each dose change and every 6 months. (1.8.8)
For people taking methylphenidate,	Replaced by:
dexamfetamine and atomoxetine, routine blood tests and ECGs are not recommended unless there is a clinical indication. (1.8.4.7)	Do not offer routine blood tests (including liver function tests) or ECGs to people taking medication for ADHD unless there is a clinical indication. (1.8.9)
Liver damage is a rare and idiosyncratic adverse effect of atomoxetine and routine liver function tests are not recommended. (1.8.4.8)	Replaced by: Do not offer routine blood tests (including liver function tests) or ECGs to people taking medication for ADHD unless there is a clinical indication. (1.8.9)
For children and young people taking methylphenidate and dexamfetamine, healthcare professionals and parents or carers should monitor changes in the potential for drug misuse and diversion, which may come with changes in circumstances and age. In these situations, modified-release methylphenidate or atomoxetine may be preferred. (1.8.4.9)	Replaced by: Healthcare professionals and parents or carers should monitor changes in the potential for stimulant misuse and diversion, which may come with changes in circumstances and age. (1.8.17)
In young people and adults, sexual	Replaced by:
dysfunction (that is, erectile and ejaculatory dysfunction) and dysmenorrhoea should be monitored as potential side effects of atomoxetine. (1.8.4.10)	Monitor young people and adults for sexual dysfunction (that is, erectile and ejaculatory dysfunction) and dysmenorrhoea as potential side effects of atomoxetine. (1.8.13)
For people taking methylphenidate,	Replaced by:

dexamfetamine or atomoxetine who have sustained resting tachycardia, arrhythmia or systolic blood pressure greater than the 95th percentile (or a clinically significant increase) measured on two occasions should have their dose reduced and be referred to a paediatrician or adult physician. (1.8.4.11)	If a person taking ADHD medication has sustained resting tachycardia (more than 120 beats per minute), arrhythmia or systolic blood pressure greater than the 95th percentile (or a clinically significant increase) measured on 2 occasions, reduce their dose and refer them to a paediatric cardiologist or adult physician. (1.8.10)
If psychotic symptoms (for example, delusions and hallucinations) emerge in children, young people and adults after starting methylphenidate or dexamfetamine, the drug should be withdrawn and a full psychiatric assessment carried out. Atomoxetine should be considered as an alternative. (1.8.4.12)	 Replaced by: For children aged 5 years and over, young people and adults with ADHD experiencing an acute psychotic or manic episode: do not offer any new medication for ADHD and stop any previously prescribed medication for ADHD. (1.7.17)
If seizures are exacerbated in a child or young person with epilepsy, or de novo seizures emerge following the introduction of methylphenidate or atomoxetine, the drug should be discontinued immediately. Dexamfetamine may be considered as an alternative in consultation with a regional tertiary specialist treatment centre. (1.8.4.13)	Replaced by: If a person with ADHD develops new seizures or a worsening of existing seizures, review their ADHD medication and stop any medication that might be contributing to the seizures. After investigation cautiously reintroduce ADHD medication if it is unlikely to be the cause of the seizures. (1.8.14)
 If tics emerge in people taking methylphenidate or dexamfetamine, healthcare professionals should consider whether: the tics are stimulant-related (tics naturally wax and wane) tic-related impairment outweighs the benefits of ADHD treatment. If tics are stimulant-related, reduce the dose of methylphenidate or dexamfetamine, consider changing to atomoxetine, or stop drug treatment. (1.8.4.14) 	 Replaced by: If a person taking stimulants develops tics, think about whether: the tics are related to the stimulant (tics naturally wax and wane) and the impairment associated with the tics outweighs the benefits of ADHD treatment. If tics are stimulant related, reduce the stimulant dose, or consider changing to guanfacine (in children aged 5 years over and young people only), atomoxetine or adding clonidine or stopping medication. (1.8.12)
Anxiety symptoms, including panic, may be precipitated by stimulants, particularly in adults with a history of coexisting anxiety. Where this is an issue, lower doses of the stimulant and/or combined treatment with an antidepressant used to treat anxiety can be used; switching to atomoxetine may be effective. (1.8.4.15)	Replaced by: Offer the same medication choices to children aged 5 years and over, young people and adults with ADHD who have an anxiety disorder, tic disorder or autism spectrum disorder as other people with ADHD. [2018] (1.7.14)
Communication between the prescriber and the child or young person should be	Replaced by:

Attention deficit hyperactivity disorder: NICE guideline short version DRAFT (September 2017) 82 of 93

improved by educating parents or carers and ensuring there are regular three-way conversations between prescriber, parent or carer and the child or young person. For adults with ADHD, and with their permission, a spouse, partner, parent, close friend or carer wherever possible should be part of these conversations. Clear instructions about how to take the drug should be offered in picture or written format, which may include information on dose, duration, side effects, dosage schedule, the need for supervision and how this should be done. (1.8.5.1)	 Encourage the person with ADHD to use the following strategies to support adherence to treatment: being responsible for their own health, including taking their medication as needed following clear instructions about how to take the medication in picture or written format, which may include information on dose, duration, side effects, dosage schedule (the instructions should stay with the medication, for example, a sticker on the side of the packet) using visual reminders to take medication regularly (for example, apps, alarms, clocks, pill dispensers, or notes on calendars or fridges) taking medication as part of their daily routine (for example, before meals or after brushing teeth) attending peer support groups (for both the person with ADHD and for the families and carers). [2018] (1.9.4)
	Throughout the recommendations the emphasis is on encouraging three way communication with the person with ADHD their parents, carers and family members and the healthcare professionals.
Healthcare professionals should consider	Replaced by:
suggesting peer-support groups for the child or young person with ADHD and their parents or carers if adherence to	Encourage the person with ADHD to use the following strategies to support adherence to treatment:
drug treatment is difficult or uncertain. (1.8.5.2)	 being responsible for their own health, including taking their medication as needed following clear instructions about how to take the medication in picture or written format, which may include information on dose, duration, side effects, dosage schedule (the instructions should stay with the medication, for example, a sticker on the side of the packet) using visual reminders to take medication regularly (for example, apps, alarms, clocks, pill

	 dispensers, or notes on calendars or fridges) taking medication as part of their daily routine (for example, before meals or after brushing teeth) attending peer support groups (for both the person with ADHD and for the families and carers). [2018] (1.9.4)
--	--

Simple drug regimens (for example, once-daily modified-release doses) are recommended for people with ADHD. (1.8.5.3)	 Replaced by: When prescribing stimulants for ADHD, think about modified-release once-daily preparations for the following reasons: convenience improving adherence reducing stigma (because there is no need to take medication at school or in the workplace) reducing problems of storing and administering controlled drugs at school the risk of stimulant misuse and diversion with immediate-release preparations their pharmacokinetic profiles. Immediate-release preparations may be suitable if more flexible dosing regimens
	are needed, or during initial titration to
	determine correct dosing levels. (1.7.25)
Healthcare professionals should encourage children and young people with ADHD to be responsible for their own health, including taking their medication as required, and support parents and carers in this endeavour. (1.8.5.4)	 Replaced by: Encourage the person with ADHD to use the following strategies to support adherence to treatment: being responsible for their own health, including taking their medication as needed following clear instructions about how to take the medication in picture or written format, which may include information on dose, duration, side effects, dosage schedule (the instructions should stay with the medication, for example, a sticker on the side of the packet) using visual reminders to take medication regularly (for example, apps, alarms, clocks, pill dispensers, or notes on calendars or fridges) taking medication as part of their daily routine (for example, before meals or after brushing teeth) attending peer support groups (for both the person with ADHD and for the families and carers). [2018] (1.9.4)
Healthcare professionals should advise parents or carers to provide the child or young person with visual reminders to take medication regularly (for example, alarms, clocks, pill boxes, or notes on	Replaced by: Encourage the person with ADHD to use the following strategies to support adherence to treatment: • being responsible for their own health, including taking their

calendars or fridges). (1.8.5.5)	 medication as needed following clear instructions about how to take the medication in picture or written format, which may include information on dose, duration, side effects, dosage schedule (the instructions should stay with the medication, for example, a sticker on the side of the packet) using visual reminders to take medication regularly (for example, apps, alarms, clocks, pill dispensers, or notes on calendars or fridges) taking medication as part of their daily routine (for example, before meals or after brushing teeth) attending peer support groups (for both the person with ADHD and for the families and carers). [2018] (1.9.4)
Healthcare professionals should advise children and young people and their parents or carers that taking medication should be incorporated into daily routines (for example, before meals or after brushing teeth). (1.8.5.6)	 Replaced by: Encourage the person with ADHD to use the following strategies to support adherence to treatment: being responsible for their own health, including taking their medication as needed following clear instructions about how to take the medication in picture or written format, which may include information on dose, duration, side effects, dosage schedule (the instructions should stay with the medication, for example, a sticker on the side of the packet) using visual reminders to take medication regularly (for example, apps, alarms, clocks, pill dispensers, or notes on calendars or fridges) taking medication as part of their daily routine (for example, before meals or after brushing teeth) attending peer support groups (for both the person with ADHD and for the families and carers). [2018] (1.9.4)
Where necessary, healthcare professionals should help parents or carers develop a positive attitude and approach in the management of	This recommendation has been deleted because it is part of the advice given to parents in the ADHD focused training programmes.

medication, which might include praise and positive reinforcement for the child or young person with ADHD. (1.8.5.7)	
Following an adequate treatment response, drug treatment for ADHD should be continued for as long as it remains clinically effective. This should be reviewed at least annually. The review should include a comprehensive assessment of clinical need, benefits and side effects, taking into account the views of the child or young person, as well as those of parents, carers and teachers, and how these views may differ. The effect of missed doses, planned dose reductions and brief periods of no treatment should be taken into account and the preferred pattern of use should also be reviewed. Coexisting conditions should be reviewed, and the child or young person treated or referred if necessary. The need for psychological and social support for the child or young person and for the parents or other carers should be assessed. (1.8.6.1)	 Replaced by: An ADHD specialist should review ADHD medication at least once a year and discuss with the person with ADHD (and their families and carers as appropriate) whether medication should be continued. The review should include a comprehensive assessment of the: preference of the child, young person or adult with ADHD (and their family or carers as appropriate) benefits, including how well the current treatment is working side effects clinical need and whether drug optimisation has been achieved impact on education and employment effects of missed doses, planned dose reductions and periods of no treatment effect of medication on existing or new mental health, physical health or neurodevelopmental conditions the need for and type of support required (for example, psychological, educational, social support) if medication has been optimised but ADHD symptoms continue to have a significant impact. [2018] (1.10.1)
Drug holidays are not routinely recommended; however, consideration should be given to the parent or carer and child or young person with ADHD working with their healthcare professional to find the best pattern of use, which may include periods without drug treatment.	Replaced by: Encourage people with ADHD to discuss any preferences to stop or change medication and to be involved in any decisions about stopping treatments. [2018] (1.10.2)
(1.8.6.2)	Consider trial periods of stopping medication or reducing the dose when assessment of the overall balance of benefits and harms suggests this may be appropriate. [2018] (1.10.3)
Following an adequate response, drug treatment for ADHD should be continued for as long as it is clinically effective. This should be reviewed annually. The review should include a comprehensive	Replaced by: An ADHD specialist should review ADHD medication at least once a year and discuss with the person with ADHD (and their families and carers as appropriate) whether medication should be continued.

assessment of clinical need, benefits and side effects, taking into account the views of the person and those of a spouse, partner, parent, close friends or carers wherever possible, and how these accounts may differ. The effect of missed doses, planned dose reductions and brief periods of no treatment should be taken into account and the preferred pattern of use should also be reviewed. Coexisting conditions should be reviewed, and the person treated or referred if necessary. The need for psychological, social and occupational support for the person and their carers should be assessed. (1.8.7.1)	 The review should include a comprehensive assessment of the: preference of the child, young person or adult with ADHD (and their family or carers as appropriate) benefits, including how well the current treatment is working side effects clinical need and whether rug optimisation has been achieved impact on education and employment effects of missed doses, planned dose reductions and periods of no treatment effect of medication on existing or new mental health, physical health or neurodevelopmental conditions the need for and type of support required (for example, psychological, educational, social support) if medication has been optimised but ADHD symptoms continue to have a significant impact. [2018] (1.10.1)
An individual treatment approach is important for adults, and healthcare professionals should regularly review (at least annually) the need to adapt patterns of use, including the effect of drug treatment on coexisting conditions and mood changes. (1.8.7.2)	Replaced by : Regularly discuss with people with ADHD, and their family members or carers, how they want to be involved in treatment planning and decisions; such discussions should take place at intervals to take account of any changes in circumstances, including developmental level, and should not happen only once. [2018] (1.5.3) An ADHD specialist should review ADHD medication at least once a year and discuss with the person with ADHD (and their families and carers as appropriate) whether medication should be continued. The review should include a comprehensive assessment of the: • preference of the child, young person or adult with ADHD (and their family or carers as appropriate) • benefits, including how well the current treatment is working • side effects • clinical need and whether drug optimisation has been achieved

 impact on education and employment effects of missed doses, planned dose reductions and periods of no treatment effect of medication on existing or new mental health, physical health or neurodevelopmental conditions the need for and type of support required (for example, psychological, educational, social support) if medication has been
optimised but ADHD symptoms continue to have a significant
5
impact[2018] (1.10.1)

1

2 Amended recommendation wording (change to meaning)

Recommendation in 2008 guideline	Recommendation in current guideline	Reason for change
 1.1.2 Mental health trusts, and children's trusts that provide mental health/child development services, should form multidisciplinary specialist ADHD teams and/or clinics for children and young people and separate teams and/or clinics for adults. These teams and clinics should have expertise in the diagnosis and management of ADHD, and should: provide diagnostic, treatment and consultation services for people with ADHD who have complex needs, or where general psychiatric services are in doubt about the diagnosis and/or management of ADHD put in place systems of communication and protocols for information sharing among paediatric, child and adolescent, forensic, and adult mental health services for people with ADHD, including arrangements for transition between child and adult 	Mental health services for children, young people and adults and child health services, should form multidisciplinary specialist ADHD teams and/or clinics for children and young people and separate teams and/or clinics for adults. These teams and clinics should have expertise in the diagnosis and management of ADHD, and should: • provide diagnostic, treatment and consultation services for people with ADHD who have complex needs, or where general psychiatric services are in doubt about the diagnosis and/or management of ADHD • put in place systems of communication and protocols for information sharing among paediatric, child and adolescent, forensic, and adult mental health services for people with ADHD, including arrangements for transition between child and adult	Updated to clarify services.

Attention deficit hyperactivity disorder: NICE guideline short version DRAFT (September 2017) 89 of 93

Every locality should develop a multi-agency group, with representatives from multidisciplinary specialist ADHD teams, paediatrics, mental health and learning disability trusts, forensic services, child and adolescent mental health services (CAMHS), the Children and Young People's Directorate (CYDP) (including services for education and social services), parent support groups and others with a significant local involvement in ADHD services. The group should:	Every locality should develop a multi-agency group, with representatives from multidisciplinary specialist ADHD teams, paediatrics, mental health and learning disability trusts, forensic services, child and adolescent mental health services (CAMHS), the Directorate for Children and Young People (DCYP) (including services for education and social services), parent support groups and others with a significant local involvement in ADHD services. The group should:	Updated with current name of Directorate for Children and Young People.
 oversee the implementation of this guideline start and coordinate local training initiatives, including the provision of training and information for teachers about the characteristics of ADHD and its basic behavioural management oversee the 	 oversee the implementation of this guideline start and coordinate local training initiatives, including the provision of training and information for teachers about the characteristics of ADHD and its basic behavioural management oversee the 	
 development and coordination of parent- training/education programmes consider compiling a comprehensive directory of information and services for ADHD including advice on how to contact relevant services and assist in the development of specialist teams. (1.1.1.3) 	 development and coordination of parent- training/education programmes consider compiling a comprehensive directory of information and services for ADHD including advice on how to contact relevant services and assist in the development of specialist teams. (1.1.3) 	
A young person with ADHD receiving treatment and care from CAMHS or paediatric services should be reassessed at school-leaving age to establish the need for continuing treatment into adulthood. If treatment is necessary, arrangements should be made for a smooth	A young person with ADHD receiving treatment and care from CAMHS or paediatric services should be reassessed at school-leaving age to establish the need for continuing treatment into adulthood. If treatment is necessary, arrangements should be made for a smooth	Updated with cross- reference to NICE's guideline on transition from children's to adult's services

Attention deficit hyperactivity disorder: NICE guideline short version DRAFT (September 2017) 91 of 93

transition to adult services with details of the anticipated treatment and services that the young person will require. Precise timing of arrangements may vary locally but should usually be completed by the time the young person is 18 years. (1.6.1.1)	transition to adult services with details of the anticipated treatment and services that the young person will require. Precise timing of arrangements may vary locally but should usually be completed by the time the young person is 18 years. See NICE's guideline on transition from children's to adults' services for young people using health or social care services. (1.1.4)	
The Department for Children, Schools and Families should consider providing more education to trainee teachers about ADHD by working with the Training and Development Agency for Schools (TDA) and relevant health service organisations to produce training programmes and guidance for supporting children with ADHD. (1.1.3.3)	The Department for Education should consider providing more education to trainee teachers about ADHD by working with the Teaching Agency (TA) and relevant health service organisations to produce training programmes and guidance for supporting children with ADHD. (1.1.9)	Updated to reflect changes in department and agency names
When a child or young person with disordered conduct and suspected ADHD is referred to a school's special educational needs coordinator (SENCO), the SENCO, in addition to helping the child with their behaviour, should inform the parents about local parent- training/education programmes. (1.2.1.2)	When a child or young person with disordered conduct and suspected ADHD is referred to a school's special educational needs coordinator (SENCO), the SENCO, in addition to helping the child with their behaviour, should inform the parents about local parent- training/education programmes. See NICE's guideline on antisocial behaviour and conduct disorders in children and young people. (1.2.4)	Updated with cross- reference to NICE's guideline on antisocial behaviour and conduct disorders in children and young people
If the child or young person's behavioural and/or attention problems suggestive of ADHD are having an adverse impact on their development or family life, consider: • a period of watchful waiting of up to 10 weeks • offering parents or carers a referral to a parent-	If the child or young person's behavioural and/or attention problems suggestive of ADHD are having an adverse impact on their development or family life, consider: • a period of watchful waiting of up to 10 weeks • offering parents or carers a referral to group-	Updated to clarify that the training should be group based and ADHD focused support

training/education	based ADHD-focused	
programme (this should not wait for a formal diagnosis of ADHD).	<mark>support</mark> (this should not wait for a formal diagnosis of ADHD).	
If the behavioural and/or attention problems persist with at least moderate impairment, the child or young person should be referred to secondary care (that is, a child psychiatrist, paediatrician, or specialist ADHD CAMHS) for assessment. (1.2.1.5)	If the behavioural and/or attention problems persist with at least moderate impairment, the child or young person should be referred to secondary care (that is, a child psychiatrist, paediatrician, or specialist ADHD CAMHS) for assessment. (1.2.7)	
For a diagnosis of ADHD, symptoms of hyperactivity/impulsivity and/or inattention should:	For a diagnosis of ADHD, symptoms of hyperactivity/impulsivity and/or inattention should:	Updated to reflect the most recent version of DSM
• meet the diagnostic criteria in DSM-IV or ICD-10 (hyperkinetic disorder) , and	• meet the diagnostic criteria in DSM- <mark>5</mark> or ICD-10 (hyperkinetic disorder) , and	
• be associated with at least moderate psychological, social and/or educational or occupational impairment based on interview and/or direct observation in multiple	cause at least moderate psychological, social and/or educational or occupational impairment based on interview and/or direct observation in multiple settings, and	
 settings, and be pervasive, occurring in two or more important settings including social, familial, educational and/or occupational settings. 	• be pervasive, occurring in two or more important settings including social, familial, educational and/or occupational settings.	
As part of the diagnostic process, include an assessment of the person's needs, coexisting conditions, social, familial and	As part of the diagnostic process, include an assessment of the person's needs, coexisting conditions, social, familial and educational or occupational	
educational or occupational circumstances and physical health. For children and young people, there should also be an assessment of	circumstances and physical health. For children and young people, there should also be an assessment of their parents' or carers'	
their parents' or carers' mental health. (1.3.1.3)	mental health. (1.3.3)	

1

2 **ISBN**: